[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 115
1. Cho BC, Ahn JB, Seong J, Roh JK, Kim JH, Chung HC, Sohn JH, Kim NK: Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients. BMC Cancer; 2008;8:8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients.
  • BACKGROUND: The objectives of this study were to evaluate long-term results of concurrent chemoradiotherapy (CRT) with 5-fluorouracil and cisplatin and the potential benefit of consolidation chemotherapy in patients with anal squamous cell carcinoma (ASCC).
  • Radiotherapy was administered at 45 Gy over 5 weeks, followed by a boost of 9 Gy to complete or partial responders.
  • Chemotherapy consisted of 5-fluorouracil (750 or 1,000 mg/m2) daily on days 1 to 5 and days 29 to 33; and, cisplatin (75 or 100 mg/m2) on day 2 and day 30.
  • Twenty-one (67.7%) received consolidation chemotherapy with the same doses of 5-fluorouracil and cisplatin, repeated every 4 weeks for maximum 4 cycles.
  • RESULTS: Nineteen patients (90.5%) completed all four courses of consolidation chemotherapy.
  • No differences in 5-year OS and DFS rates between patients treated with CRT alone and CRT with consolidation chemotherapy was observed.
  • CONCLUSION: our study shows that CRT with 5-FU and cisplatin, with or without consolidation chemotherapy, was well tolerated and proved highly encouraging in terms of long-term survival and the preservation of anal function in ASCC.
  • Further trials with a larger patient population are warranted in order to evaluate the potential role of consolidation chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Fluorouracil / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1989 Jun 7;81(11):850-6 [2724350.001]
  • [Cites] Dis Colon Rectum. 1987 Jul;30(7):495-502 [3109860.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1153-60 [2599903.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Ann Surg. 1992 Feb;215(2):150-6 [1546901.001]
  • [Cites] Dis Colon Rectum. 1992 Jun;35(6):574-7; discussion 577-8 [1587176.001]
  • [Cites] Radiother Oncol. 1993 Jun;27(3):209-15 [8210457.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jul 1;35(4):745-9 [8690640.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3121-5 [8955657.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):575-81 [9261527.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Dec 1;39(5):1099-105 [9392550.001]
  • [Cites] Radiother Oncol. 1998 Mar;46(3):249-56 [9572617.001]
  • [Cites] Int J Clin Oncol. 2004 Dec;9 Suppl 3:1-82 [15818867.001]
  • [Cites] Cancer. 2005 Dec 15;104(12):2650-7 [16284984.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S123-8 [16399449.001]
  • [Cites] Oncologist. 2007 Apr;12(4):451-64 [17470688.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3229-34 [18490648.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1195-202 [12599225.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2460-5 [12829663.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2933-9 [12885812.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2057-61 [14647138.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1727-33 [526911.001]
  • [Cites] J Clin Gastroenterol. 1984 Jun;6(3):257-9 [6539351.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2062-8 [6435851.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] Cancer Res. 1986 Aug;46(8):3876-85 [3731062.001]
  • [Cites] Am J Med. 1989 Aug;87(2):221-4 [2527006.001]
  • (PMID = 18194582.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2245963
  •  go-up   go-down


2. Mondal SK: Primary squamous cell carcinoma of the cecum. J Cancer Res Ther; 2009 Oct-Dec;5(4):328-30
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary squamous cell carcinoma of the cecum.
  • Primary squamous cell carcinoma (SSC) of cecum is a very rare malignant neoplasm.
  • Clinical features were that of an adenocarcinoma of the colon.
  • Postoperative chemotherapy was given for 6 months to eradicate any micrometastasis.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cecal Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20160376.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Chen ZF, Zheng SB, Wu P, Zhang P, Jiang YD, Zhao SC, Mao XM, Chen ZR, Shan ZF: [Synchronous squamous cell carcinoma of the renal pelvis and squamous cell carcinoma of the ureter: report of two cases and review of literature]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec;30(12):2765-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous squamous cell carcinoma of the renal pelvis and squamous cell carcinoma of the ureter: report of two cases and review of literature].
  • OBJECTIVE: To study the clinicopathological characteristics of synchronous squamous cell carcinoma (SCC) of the renal pelvis and SCC of the ureter.
  • In case 1, a 68-year-old man with hematuria for a month, imaging modalities revealed a right renal pelvis tumor and a right distal ureter tumor.
  • Case 2, a 60-year-old man with the complaint of lower abdominal pain and left flank pain for a month, was diagnosed as left distal ureteral stone in another hospital.
  • The pathological report demonstrated SCC, and the patient was transferred to our hospital for further treatment.
  • Neither of patients received adjuvant radiotherapy/chemotherapy.
  • RESULTS: Moderately differentiated SCC was reported in both of renal pelvis and ureter in case 1 and the tumor invaded the subepithelial connective tissue in the renal pelvis and superficial muscle in the ureter.
  • In case 2, moderately differentiated SCC of the left renal pelvis with colon metastasis and poorly differentiated SCC of the ureter was reported with two retroperitoneal lymph node metastases.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Kidney Neoplasms / complications. Kidney Pelvis. Ureteral Neoplasms / complications

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21177201.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


Advertisement
4. Sameer AS, Syeed N, Chowdri NA, Parray FQ, Siddiqi MA: Squamous cell carcinoma of rectum presenting in a man: a case report. J Med Case Rep; 2010;4:392

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of rectum presenting in a man: a case report.
  • BACKGROUND: Primary squamous cell carcinomas of the colorectum are very uncommon.
  • Until now, to the best of our knowledge, only 114 cases of squamous cell carcinoma in the colorectum exist in the reported literature.
  • Here we report a case of squamous cell carcinoma of the rectum in the ethnic Kashmiri population in northern India.
  • CASE PRESENTATION: The case of a 60-year-old male patient (Asian) with a pure squamous cell carcinoma of the rectum is presented here.
  • The patient underwent a curative surgery with concomitant chemotherapy.
  • CONCLUSION: The prognosis for squamous cell carcinoma of the colorectum is worse than for that of adenocarcinoma, because of the delayed diagnosis.
  • The etiopathogenicity of squamous cell carcinoma of the colorectum is discussed.
  • Surgical resection of the lesion seems to be the treatment of choice.
  • Chemotherapy also helps in improvement of the prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1999 Jan;42(1):102-9 [10211528.001]
  • [Cites] Gastroenterology. 2001 Mar;120(4):988-94 [11231953.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):341-6 [11289278.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):919-25 [17527081.001]
  • [Cites] Cancer. 1978 Oct;42(4):1879-82 [361214.001]
  • [Cites] Dis Colon Rectum. 1985 Dec;28(12):967-72 [4064861.001]
  • [Cites] Dis Colon Rectum. 1982 Jul-Aug;25(5):483-7 [7094788.001]
  • [Cites] Cancer. 1981 Feb 1;47(3):602-9 [7226009.001]
  • [Cites] Eur J Surg Oncol. 2002 Sep;28(6):657-60 [12359204.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1535-40 [12432303.001]
  • [Cites] Clin Colorectal Cancer. 2001 May;1(1):55-8 [12445380.001]
  • [Cites] J Urol. 2003 Jan;169(1):280 [12478160.001]
  • [Cites] Indian J Cancer. 2003 Jul-Sep;40(3):118-9 [14716117.001]
  • [Cites] Eur J Cancer Care (Engl). 2005 Mar;14(1):70-4 [15698388.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):442-8 [16365727.001]
  • [Cites] Pathology. 2006 Feb;38(1):74-6 [16484015.001]
  • [Cites] Int J Colorectal Dis. 2007 Apr;22(4):445-7 [16932927.001]
  • [Cites] Endoscopy. 2008 Sep;40 Suppl 2:E45-6 [18300203.001]
  • [Cites] Colorectal Dis. 2009 Feb;11(2):191-7 [18462236.001]
  • [Cites] Eur J Cancer. 2008 Nov;44(16):2340-3 [18707873.001]
  • [Cites] World J Gastroenterol. 2009 Sep 21;15(35):4380-6 [19764088.001]
  • [Cites] Saudi J Gastroenterol. 2009 Oct-Dec;15(4):244-52 [19794270.001]
  • [Cites] Rev Invest Clin. 1996 Nov-Dec;48(6):453-6 [9028152.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 May;19(5):719-20 [11343961.001]
  • [Cites] Pathology. 2001 Aug;33(3):312-4 [11523931.001]
  • [Cites] G E N. 1992 Oct-Dec;46(4):331-5 [1340840.001]
  • [Cites] Int J Colorectal Dis. 1992 Sep;7(3):144-7 [1402312.001]
  • [Cites] Dis Colon Rectum. 2007 Sep;50(9):1393-400 [17661147.001]
  • [Cites] Eur J Surg Oncol. 1991 Aug;17(4):392-4 [1845295.001]
  • [Cites] Cancer. 1986 Sep 1;58(5):1126-30 [2425931.001]
  • [Cites] APMIS. 1988 Sep;96(9):839-44 [3166810.001]
  • [Cites] Hum Pathol. 1988 Mar;19(3):362-4 [3278968.001]
  • [Cites] Dis Colon Rectum. 1988 Apr;31(4):323-6 [3282843.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1987 Jul;9(4):315-6 [3315530.001]
  • [Cites] J Surg Oncol. 1987 Jun;35(2):117-9 [3586681.001]
  • [Cites] Eur J Surg Oncol. 1987 Oct;13(5):455-8 [3666162.001]
  • [Cites] Dis Colon Rectum. 1986 Oct;29(10):665-7 [3757710.001]
  • [Cites] Arch Surg. 1985 Oct;120(10):1176-7 [4038062.001]
  • [Cites] Br J Surg. 1972 May;59(5):410-2 [5021150.001]
  • [Cites] Dis Colon Rectum. 1971 May-Jun;14(3):213-7 [5139957.001]
  • [Cites] J Pathol. 1979 Nov;129(3):139-47 [529012.001]
  • [Cites] JAMA. 1970 Jun 1;212(9):1511-3 [5467545.001]
  • [Cites] Am J Clin Pathol. 1981 Apr;75(4):581-4 [6261578.001]
  • [Cites] Dig Dis Sci. 1983 Oct;28(10):918-22 [6352206.001]
  • [Cites] Am J Surg Pathol. 1978 Mar;2(1):47-54 [637188.001]
  • [Cites] Vopr Onkol. 1984;30(8):76-83 [6485288.001]
  • [Cites] Tumori. 1984 Feb 29;70(1):99-103 [6710610.001]
  • [Cites] Dis Colon Rectum. 1983 Mar;26(3):188-91 [6825528.001]
  • [Cites] Dis Colon Rectum. 1983 Apr;26(4):279-82 [6839899.001]
  • [Cites] Minerva Dietol Gastroenterol. 1983 Jan-Mar;29(1):33-8 [6843855.001]
  • [Cites] Pathologe. 1982 Nov;3(6):359-64 [7156057.001]
  • [Cites] Int J Dermatol. 1993 Nov;32(11):846 [8270353.001]
  • [Cites] Surg Today. 1994;24(1):75-9 [8054782.001]
  • [Cites] Dis Colon Rectum. 1996 Nov;39(11):1265-8 [8918436.001]
  • [Cites] Clin Colorectal Cancer. 2002 Feb;1(4):243-8 [12450423.001]
  • [Cites] Am J Gastroenterol. 1962 Jan;37:48-54 [14006818.001]
  • [Cites] Br J Surg. 1965 Sep;52:666-8 [14338313.001]
  • [Cites] World J Surg Oncol. 2006;4:49 [16895595.001]
  • [Cites] Can J Gastroenterol. 2007 Jan;21(1):47-50 [17225882.001]
  • [Cites] Br J Surg. 1968 Apr;55(4):273-6 [5644391.001]
  • [Cites] Arch Pathol. 1967 Jul;84(1):77-80 [6027742.001]
  • [Cites] Dis Colon Rectum. 1967 Jul-Aug;10(4):288-97 [6037409.001]
  • [Cites] Dis Colon Rectum. 1967 Nov-Dec;10(6):435-42 [6066367.001]
  • [Cites] Acta Chir Belg. 1994 Nov-Dec;94(6):318-20 [7846991.001]
  • (PMID = 21118539.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3014960
  •  go-up   go-down


5. Anagnostopoulos G, Sakorafas GH, Kostopoulos P, Grigoriadis K, Pavlakis G, Margantinis G, Vugiouklakis D, Arvanitidis D: Squamous cell carcinoma of the rectum: a case report and review of the literature. Eur J Cancer Care (Engl); 2005 Mar;14(1):70-4
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the rectum: a case report and review of the literature.
  • Squamous cell carcinoma of the colon and rectum are extremely rare neoplasms.
  • Surgery is the most effective therapy, and adjuvant chemotherapy and radiotherapy should be considered, especially for node-positive patients.
  • We present a patient with squamous cell carcinoma of the middle rectum who underwent abdominoperineal resection and postoperative adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell. Rectal Neoplasms
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant / methods. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cancer Care (Engl). 2005 Dec;14(5):465 [16274470.001]
  • (PMID = 15698388.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 55
  •  go-up   go-down


6. Copur S, Ledakis P, Novinski D, Mleczko KL, Frankforter S, Bolton M, Fruehling RM, VanWie E, Norvell M, Muhvic J: Squamous cell carcinoma of the colon with an elevated serum squamous cell carcinoma antigen responding to combination chemotherapy. Clin Colorectal Cancer; 2001 May;1(1):55-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the colon with an elevated serum squamous cell carcinoma antigen responding to combination chemotherapy.
  • Primary squamous cell colorectal carcinomas are uncommon, and their characteristics are not well known.
  • The most commonly reported anatomic locations are the rectum and the proximal colon.
  • Clinical features and common diagnostic methods do not easily differentiate squamous cell colorectal carcinomas from adenocarcinomas.
  • Because of their extremely rare occurrence, it is difficult to study their natural course, clinical behavior, and response to therapy.
  • This report presents the case of a pure squamous cell colorectal cancer and provides a brief review of the literature, which includes 60 previously published cases.
  • The case of a patient with T3N2M0 primary squamous cell carcinoma of the rectosigmoid colon, which was initially treated with abdominoperineal resection followed by adjuvant chemotherapy and radiation, is presented.
  • During the follow-up, an elevated squamous cell carcinoma antigen (SCC Ag) level led to restaging computed tomography scans, which confirmed recurrent metastatic disease in the liver.
  • Response to chemotherapy with a decrease in tumor size correlated with a decrease in the serum SCC Ag level.
  • Although SCC Ag has been used as a tumor marker for squamous cell cancers of the lung, head and neck, uterine cervix, and esophagus, this is the first reported case of a squamous cell colon carcinoma presenting with an elevated SCC Ag at the time of recurrence.
  • In addition, this patient showed an objective partial response to combination chemotherapy, with a decrease in the serum level of this tumor marker.
  • [MeSH-major] Antigens, Neoplasm / blood. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carcinoma, Squamous Cell / drug therapy. Colonic Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Serpins
  • [MeSH-minor] Cisplatin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12445380.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Serpins; 0 / squamous cell carcinoma-related antigen; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Brammer RD, Taniere P, Radley S: Metachronous squamous-cell carcinoma of the colon and treatment of rectal squamous carcinoma with chemoradiotherapy. Colorectal Dis; 2009 Feb;11(2):219-20
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metachronous squamous-cell carcinoma of the colon and treatment of rectal squamous carcinoma with chemoradiotherapy.
  • Rectal squamous-cell carcinoma is a rare tumour with an incidence of less than 1 per 1000 cases.
  • The patient developed a metastasis in the spleen and a further squamous tumour in the right colon, both of which were successfully resected.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Colonic Neoplasms / secondary. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy. Splenic Neoplasms / secondary
  • [MeSH-minor] Female. Humans. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18477022.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Michalet V, Gaudin JL, Bancel B, El Khaddari S, Baulieux J, Rode A, Souquet JC: [Squamous cell carcinoma of the celiac area. Report of a case and review of the literature]. Gastroenterol Clin Biol; 2002 Dec;26(12):1168-71
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the celiac area. Report of a case and review of the literature].
  • Primary squamous cell carcinoma of the pancreas or of the stomach is rare and represents a controversial entity.
  • The unusual case of a 50-year-old woman with a large squamous cell carcinoma located in the celiac area and involving liver, stomach and pancreas, is reported here.
  • The microscopic diagnosis was well-differentiated squamous cell carcinoma without glandular structure.
  • Following the procedure, search for another possible primary lesion (esophagus, anus, colon, lung, head and neck, pelvic floor) was performed.
  • In this context, final diagnosis was primary gastric or pancreatic squamous cell carcinoma.
  • Subsequent radiation combined with chemotherapy was instituted, allowing complete remission.
  • Pathogenesis of gastric as well as pancreatic primary squamous cell carcinoma remains obscure and controversial.
  • [MeSH-major] Carcinoma, Squamous Cell. Liver Neoplasms. Neoplasms, Multiple Primary. Pancreatic Neoplasms. Stomach Neoplasms
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Female. Humans. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Recurrence, Local / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12520205.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 15
  •  go-up   go-down


9. Akay S, Ozütemiz O, Doganavsargil B: Severe colitis after administration of UFT chemotherapy for temporal bone carcinoma. Expert Opin Drug Saf; 2004 Mar;3(2):89-92
MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe colitis after administration of UFT chemotherapy for temporal bone carcinoma.
  • UFT (Uftoral), a blend of uracil and Tegafur, is an antitumour agent for oral administration that is presumed to maintain the concentration of 5-fluorouracil (5-FU) in tumour tissue.
  • As a result of increased use of high-dose 5-FU-based chemotherapy for various solid tumours, complicated drug-induced colitis is more frequently observed.
  • The authors present the case of a patient with locally advanced temporal bone carcinoma who developed haematochezia during a course of chemotherapy with UFT.
  • Colonoscopy of the patient showed bleeding petechia-like lesions and superficial inflammatory exudate, whilst histology revealed non-specific inflammatory changes of the colon mucosa.
  • As the haematochezia improved with supportive treatment, neutropenia complicated the clinical picture.
  • This patient developed life-threatening UFT toxicity without an exon-14 DPD gene mutation.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Colonic Diseases / etiology. Gastrointestinal Hemorrhage / etiology. Neoplasms, Squamous Cell / drug therapy. Skull Neoplasms / drug therapy. Tegafur / adverse effects. Temporal Bone. Uracil / adverse effects
  • [MeSH-minor] Colonoscopy. Drug Combinations. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15006714.001).
  • [ISSN] 1474-0338
  • [Journal-full-title] Expert opinion on drug safety
  • [ISO-abbreviation] Expert Opin Drug Saf
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil
  •  go-up   go-down


10. Taniguchi H, Sakagami J, Suzuki N, Hasegawa H, Shinoda M, Tosa M, Baba T, Yasuda H, Kataoka K, Yoshikawa T: Adenoendocrine cell carcinoma of the gallbladder clinically mimicking squamous cell carcinoma. Int J Clin Oncol; 2009 Apr;14(2):167-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoendocrine cell carcinoma of the gallbladder clinically mimicking squamous cell carcinoma.
  • We present the case of a 62-year-old Japanese man whose histological diagnosis was adenoendocrine cell carcinoma of the gallbladder at autopsy, but whose antemortem diagnosis was squamous cell carcinoma.
  • Abdominal computed tomography revealed a large tumor on the gallbladder involving the adjacent liver, colon, and duodenum, with multiple metastases in the greater omentum and paraportal lymph nodes.
  • The serum level of squamous cell carcinoma antigen (SCCA) was high, whereas that of carbohydrate antigen (CA) 19-9, as well as that of carcinoembryonic antigen (CEA) was within the normal range.
  • Due to these clinical features, we first suspected advanced squamous cell carcinoma of the gallbladder.
  • Though tumor regression was achieved and his serum SCCA level normalized after 3 months, the patient rejected additional chemotherapy and died 8 months after the diagnosis.
  • The histopathological findings made by autopsy demonstrated the tumor to be an adenoendocrine cell carcinoma without squamous carcinoma cells.
  • The case is interesting in that the clinical features were similar to those of squamous cell carcinoma of the gallbladder.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Small Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2001 Jan;98(1):53-7 [11201126.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):355-74 [16139391.001]
  • [Cites] Curr Opin Oncol. 2005 May;17(3):218-24 [15818164.001]
  • [Cites] Tumour Biol. 1998;19(6):488-93 [9817978.001]
  • [Cites] Int J Oncol. 2006 Nov;29(5):1231-5 [17016656.001]
  • [Cites] Br J Cancer. 2004 Nov 15;91(10):1769-74 [15505626.001]
  • [Cites] Surg Today. 2006;36(9):849-52 [16937295.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1493-7 [1516000.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(1):97-101 [10982599.001]
  • [Cites] J Surg Oncol. 2007 Feb 1;95(2):129-34 [17262729.001]
  • [Cites] Int J Cancer. 1991 Feb 1;47(3):376-9 [1704354.001]
  • [Cites] Hepatogastroenterology. 2001 Nov-Dec;48(42):1588-93 [11813580.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):572-80 [17594719.001]
  • [Cites] Jpn J Clin Oncol. 2007 Nov;37(11):843-51 [17942578.001]
  • (PMID = 19390950.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Serpins; 0 / squamous cell carcinoma-related antigen
  •  go-up   go-down


11. Place RJ, Gregorcyk SG, Huber PJ, Simmang CL: Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. Dis Colon Rectum; 2001 Apr;44(4):506-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome analysis of HIV-positive patients with anal squamous cell carcinoma.
  • PURPOSE: With improved antiretroviral therapy, HIV-positive patients are achieving a longer life expectancy.
  • An increased incidence of anal squamous cell carcinomas has been noted in these patients.
  • The purpose of this study was to determine the outcome of HIV-positive patients with anal squamous cell carcinomas.
  • We identified 73 patients with anal squamous cell carcinoma treated at the University of Texas Southwestern Medical Center affiliated hospitals; 23 were HIV positive (18 had AIDS).
  • In the HIV-positive group, 9 had in situ squamous carcinomas and 14 had invasive squamous cell carcinomas.
  • Data collected included age, CD4 count, treatment, complications, and survival; these data were analyzed by Student's t-test.
  • Those with squamous cell cancer of the anus were offered radiation therapy and chemotherapy.
  • Beginning in 1998, all patients received highly active antiretroviral therapy before treatment.
  • Seven of 14 anal squamous cell carcinoma patients had their therapy adjusted owing to toxicity.
  • Mean age was 42 years for anal squamous cell carcinoma patients and 36 years for squamous cell carcinoma in situ patients (P = 0.05).
  • Mean CD4 count was 222 cells/ml in patients with infiltrating carcinoma and 200 in the in situ patients (P = NS).
  • One-year and five-year mortality rates, respectively, were 40 percent and 80 percent for infiltrating carcinoma patients and 17 percent and 50 percent for the in situ patients.
  • Eight (all with infiltrating carcinoma) of the 10 patients who died had persistent anal disease, but none had metastasis.
  • A low CD4 count at diagnosis without highly active antiretroviral therapy predicts a poor prognosis.
  • Because these patients appear to succumb to their HIV status and not the anal disease, anal squamous cell carcinoma should be included with cervical squamous cell carcinoma as an AIDS-defining illness.
  • HIV-positive patients, particularly AIDS patients, with invasive anal cancers and without effective antiretroviral therapy obtain little benefit and significant toxicity from current radiation therapy and chemotherapy.
  • Initiation of highly active antiretroviral therapy in HIV-positive patients before radiation therapy and chemotherapy are begun may decrease toxicity and improve survival.
  • [MeSH-major] Anus Neoplasms / complications. Carcinoma in Situ / complications. Carcinoma, Squamous Cell / complications. HIV Infections / complications
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Combined Modality Therapy. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome


12. Galbfach PJ, Sygut AR, Spychalski MI, Winiarski MJ, Dziki AJ: [Squamous cell carcinoma of caecum--case report]. Pol Merkur Lekarski; 2009 Jun;26(156):640-1
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of caecum--case report].
  • Squamous cell cancer is a very rare malignancy in colon and rectum.
  • It accounts for 0.05-0.1% of all types of cancers in this localization.
  • In the article we present a case of 77 year old women who was operated due to tumor of caecum which infiltrated the proximal transverse colon.
  • Histopathological examination of removed tumor revealed squamous cell carcinoma of caecum in pT4 stage.
  • In the Clinic retrospective material squamous cell cancer of colon accounts for 0.07% of the total colon cancer cases.
  • The patient was disqualified from post-operative chemotherapy because of the age and general condition.
  • Despite the radical surgical treatment the course of the disease was rapid.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Cecal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19711732.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


13. Kouroussis C, Samonis G, Androulakis N, Souglakos J, Voloudaki A, Dimopoulos MA, Kotsakis T, Kakolyris S, Kalbakis K, Georgoulias V: Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases. Am J Clin Oncol; 2000 Jun;23(3):309-13
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases.
  • Five cases of acute neutropenic enterocolitis complicating taxane-based chemotherapy are described.
  • During a 34-month period, our department administered 4,600 courses of taxane-based (paclitaxel and docetaxel) chemotherapy to 800 cancer patients.
  • Seven to 10 days postchemotherapy in five patients (0.1% of the given courses), neutropenic fever, abdominal pain, rebound tenderness, and grade II-IV diarrhea (bloody in two cases) developed.
  • Two patients had oral candidiasis, and in two others septic shock developed.
  • Computed tomography scans of the abdomen revealed in all patients thickening of the colon wall and pericolic edema, and a pericolic abscess was revealed in three of them.
  • In conclusion, acute neutropenic enterocolitis is a severe complication of taxane-based chemotherapy.
  • Early diagnosis and appropriate conservative treatment leads to complete recovery.
  • [MeSH-minor] Acute Disease. Aged. Anti-Bacterial Agents / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Lung Neoplasms / drug therapy. Male. Middle Aged. Ovarian Neoplasms / drug therapy. Recombinant Proteins. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10857900.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Recombinant Proteins; 0 / Taxoids; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


14. Chand M, Thomas RJ, Dabbas N, Bateman AC, Royle GT: Soft Tissue Metastases as the First Clinical Manifestation of Squamous Cell Carcinoma of the Esophagus: Case Report. World J Oncol; 2010 Jun;1(3):135-137

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft Tissue Metastases as the First Clinical Manifestation of Squamous Cell Carcinoma of the Esophagus: Case Report.
  • Soft tissue metastases are an uncommon presenting feature for primary solid tumours.
  • This case highlights a rare presentation in which a soft tissue mass is the first clinical manifestation of a widespread disseminated malignancy of the esophagus.
  • Core biopsies revealed squamous carcinoma.
  • Immunohistochemistry suggested the most likely diagnosis was that of metastatic carcinoma with a number of potential primary sites.
  • Computed tomography scanning showed widespread metastatic disease, including lung, liver, kidney, omentum, subcutaneous and intramuscular lesions.
  • The distal esophagus was noted to be circumferentially thickened.
  • Finally, upper gastrointestinal endoscopy revealed carcinoma of the esophagus.
  • The patient remains well awaiting esophageal stenting and palliative chemotherapy.
  • In conclusion, it is important to be able to distinguish the origin of a soft-tissue swelling as the management will depend significantly on the histological type.
  • Soft-tissue metastases are rarely encountered as a presenting sign of an occult cancer.
  • Primary cancers that most commonly metastasise to soft tissues include those arising within the lung, colon and kidney.
  • This case demonstrates the utility of biopsy in the investigation of soft tissue masses when the clinical presentation is unusual.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Plast Surg. 1993 Oct;31(4):377-8 [8239441.001]
  • [Cites] Clin Orthop Relat Res. 1993 Nov;(296):213-7 [8222429.001]
  • [Cites] Br J Surg. 1970 Jul;57(7):529-30 [5427475.001]
  • [Cites] Cancer. 2008 Jan 1;112(1):193-203 [18040999.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):526-34 [10947022.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3780-3 [17704428.001]
  • [Cites] Skeletal Radiol. 2000 May;29(5):270-4 [10883446.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):508-11 [17081724.001]
  • [Cites] Ann Thorac Surg. 1996 May;61(5):1525-6 [8633975.001]
  • (PMID = 29147193.001).
  • [ISSN] 1920-454X
  • [Journal-full-title] World journal of oncology
  • [ISO-abbreviation] World J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Biopsy / Esophagus / Occult cancer / Soft tissue metastasis / Squamous cell carcinoma
  •  go-up   go-down


15. Rajkumar D, Prakash A, Arya SV, Sinha AN: Adenosquamous carcinoma of colon. Indian J Gastroenterol; 2001 Nov-Dec;20(6):241-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenosquamous carcinoma of colon.
  • Primary adenosquamous carcinoma of the colon is an aggressive entity.
  • We report a 41-year-old man with a combination of adenocarcinoma and squamous cell carcinoma of the cecum, treated by right hemicolectomy and ileo-transverse anastomosis.
  • Postoperatively he received adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Cecal Neoplasms / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11817779.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


16. Shirai K, O'Brien PE: Molecular targets in squamous cell carcinoma of the head and neck. Curr Treat Options Oncol; 2007 Jun;8(3):239-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular targets in squamous cell carcinoma of the head and neck.
  • Despite a significant decrease in smoking, about 40,000 new patients are diagnosed with carcinoma of the head and neck annually in the United States, and 11,000 of them succumb to their disease.
  • More than 90% of these cancers are squamous cell carcinoma.
  • The survival rates of patients with squamous cell carcinoma of the head and neck (SCCHN) have not improved significantly despite multimodality therapy including surgery, radiation therapy, and chemotherapy.
  • Recently, molecular targeted agents have shown significant improvement in clinical outcomes in chronic myelogeneous leukemia with imatinib, breast cancer with trastuzumab, colon cancer with bevacizumab and cetuximab, and renal cell cancer with sorafenib and sunitinib.
  • How best to integrate these agents with the traditional treatment modalities of surgery, radiotherapy, and cytotoxic chemotherapy is of vital importance but has yet to be determined.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cetuximab. Drug Design. Humans

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9953-61 [16267020.001]
  • [Cites] Cancer Lett. 2007 Apr 18;248(2):269-79 [16996205.001]
  • [Cites] Oncologist. 2004;9 Suppl 1:2-10 [15178810.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1207-18 [16909423.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):77-85 [14701768.001]
  • [Cites] Expert Opin Biol Ther. 2005 Aug;5(8):1085-93 [16050785.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1980-7 [12743152.001]
  • [Cites] Cancer Cell Int. 2005 Jun 01;5(1):18 [15929791.001]
  • [Cites] Br J Cancer. 2005 Mar 28;92(6):1063-8 [15756277.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5386-403 [15983388.001]
  • [Cites] Mol Biol Med. 1983 Dec;1(5):511-29 [6094961.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 May;7(5):359-71 [16633338.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):775-81 [10952783.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):769-84 [16955068.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5355-62 [15289342.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1072-8 [16505426.001]
  • [Cites] Head Neck. 2013 Jul;35(7):942-8 [22791234.001]
  • [Cites] Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):5-13 [16736978.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5235-46 [16051966.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7350-6 [12499279.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8646-54 [16314626.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3889-96 [15897590.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8418-24 [16322304.001]
  • (PMID = 17962911.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; PQX0D8J21J / Cetuximab
  • [Number-of-references] 60
  •  go-up   go-down


17. Gelas T, Peyrat P, Francois Y, Gerard JP, Baulieux J, Gilly FN, Vignal J, Glehen O: Primary squamous-cell carcinoma of the rectum: report of six cases and review of the literature. Dis Colon Rectum; 2002 Nov;45(11):1535-40
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary squamous-cell carcinoma of the rectum: report of six cases and review of the literature.
  • Squamous-cell carcinoma is a rare pathologic curiosity.
  • In two cases neoadjuvant combination of external beam radiotherapy and chemotherapy and in one case neoadjuvant contact x-ray treatment were performed.
  • This treatment was followed by external beam radiotherapy in two cases and by chemotherapy in two cases, in patients with lymph node involvement.
  • CONCLUSION: The etiopathogenicity of squamous-cell carcinoma of the rectum is discussed.
  • Surgical resection seems to be the most important treatment.
  • Chemotherapy and especially radiotherapy may have some indications.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colonoscopy. Diagnosis, Differential. Fatal Outcome. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Prognosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12432303.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


18. Nahas CS, Shia J, Joseph R, Schrag D, Minsky BD, Weiser MR, Guillem JG, Paty PB, Klimstra DS, Tang LH, Wong WD, Temple LK: Squamous-cell carcinoma of the rectum: a rare but curable tumor. Dis Colon Rectum; 2007 Sep;50(9):1393-400
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous-cell carcinoma of the rectum: a rare but curable tumor.
  • PURPOSE: This study was designed to evaluate one institution's experience with treatment outcomes for rectal squamous-cell carcinoma.
  • METHODS: Using our prospective Colorectal Database, we identified patients diagnosed with rectal squamous-cell carcinoma at our institution between 1983 and 2005.
  • Pathology was rereviewed, tumor immunophenotype was compared to control cases of anal squamous-cell carcinoma and rectal adenocarcinoma, treatment modalities and outcomes were analyzed.
  • Median distal extent of tumors was 7 (range, 5-8) cm from the anal verge.
  • Treatment included chemotherapy only (n = 1), chemoradiation only (n = 2), induction chemotherapy followed by chemoradiation and surgery (n = 2), chemoradiation followed by surgery (n = 5), and surgery followed by chemoradiation (n = 2).
  • The chemotherapy regimen was 5-fluorouracil-based.
  • Radiotherapy total dose was 50.4 Gy (1.8 Gy/day, daily x 5) external iliac and inguinal nodes were not included in the radiation field.
  • Complete clinical responders to chemoradiation (n = 2) received no further treatment.
  • Immunophenotypical analysis showed similar keratin expression profile between rectal squamous-cell carcinoma (n = 5) and rectal adenocarcinoma (n = 5), which is different from anal squamous-cell carcinoma (n = 10).
  • CONCLUSIONS: Our data suggest that most patients treated with upfront chemoradiation therapy followed by surgery did well.
  • Immunohistochemistry suggests a common cellular origin for rectal squamous-cell carcinoma and rectal adenocarcinoma, which is different from anal squamous-cell carcinoma.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / therapy. Colectomy. Fluorouracil / therapeutic use. Rectal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Follow-Up Studies. Humans. Immunohistochemistry. Keratins / metabolism. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome. United States / epidemiology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17661147.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 68238-35-7 / Keratins; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Hitt R, Martín P, Hidalgo M: Cetuximab in squamous cell carcinoma of the head and neck. Future Oncol; 2006 Aug;2(4):449-57
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab in squamous cell carcinoma of the head and neck.
  • Surgery and radiotherapy are the standard treatment options for patients with squamous cell carcinoma of the head and neck (SCCHN).
  • Chemotherapy and chemoradiotherapy are new alternatives for locally advanced disease, particularly induction chemotherapy for patients with unresectable tumors.
  • In recurrent/metastatic disease and after progression to platin-based regimens, no treatments other than best supportive care are currently available.
  • This is a tyrosine kinase membrane receptor and has a clear implication in angiogenesis, tumor progression and resistance to different cancer treatments.
  • The drug is active in colon cancer and is currently being tested in SCCHN patients.
  • For locally advanced disease, cetuximab/radiotherapy combination has demonstrated a benefit in survival when compared with radiotherapy alone as radical treatment.
  • Cetuximab is an active treatment in platin-refractory patients with recurrent/metastatic disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16922611.001).
  • [ISSN] 1479-6694
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; PQX0D8J21J / Cetuximab
  • [Number-of-references] 32
  •  go-up   go-down


20. Perera D, Pathma-Nathan N, Rabbitt P, Hewett P, Rieger N: Sentinel node biopsy for squamous-cell carcinoma of the anus and anal margin. Dis Colon Rectum; 2003 Aug;46(8):1027-9; discussion 1030-1
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel node biopsy for squamous-cell carcinoma of the anus and anal margin.
  • PURPOSE: The majority of anal tumors are squamous-cell carcinomas.
  • They are best treated by combination of chemotherapy and radiotherapy.
  • METHODS: Patients with anal squamous-cell carcinoma had four injections of 0.2 ml of antimony sulfide (30 MBq) around the tumor.
  • RESULTS: This procedure was performed on 12 patients.
  • In two patients, metastatic squamous-cell carcinoma was identified histologically in the sentinel node.
  • CONCLUSION: We advocate that this as a safe technique for detecting metastatic disease in the inguinal nodes in patients with anal squamous-cell carcinoma.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Sentinel Lymph Node Biopsy / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12907894.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Ohtani K, Sakamoto H, Masaoka N, Shimada K, Kanaeda T, Kurihara M, Nagai N, Satoh K: A case of rapidly growing ovarian squamous cell carcinoma successfully controlled by weekly paclitaxel-carboplatin administration. Gynecol Oncol; 2000 Dec;79(3):515-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of rapidly growing ovarian squamous cell carcinoma successfully controlled by weekly paclitaxel-carboplatin administration.
  • BACKGROUND: Primary squamous cell carcinoma of the ovary is uncommon and has a poor prognosis.
  • Because of its rarity, the effective postoperative treatment is unknown.
  • CASE: A 53-year-old woman had rapidly growing primary squamous cell carcinoma of the ovary that metastasized to the abdominal wall and transverse colon after maximum cytoreductive surgery.
  • The tumor was resistant to primary chemotherapy with cisplatin, vincristine, mitomycin C, and bleomycin.
  • A combination of paclitaxel and carboplatin was used for second-line chemotherapy and was repeated every week.
  • The patient tolerated the chemotherapy well and demonstrated a pathological complete response in the abdominal metastases following the five courses of chemotherapy.
  • CONCLUSION: Weekly paclitaxel-carboplatin administration may be a safe and effective treatment for advanced and rapidly growing ovarian squamous cell carcinoma with primary resistance to chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / secondary. Carboplatin / administration & dosage. Colonic Neoplasms / drug therapy. Colonic Neoplasms / secondary. Drug Administration Schedule. Female. Humans. Middle Aged. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 11104632.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


22. Yildirim Y, Akcali Z, Bilezikci B, Ozyilkan O: Primary squamous cell carcinoma of the stomach: a case report. Tumori; 2005 Sep-Oct;91(5):440-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary squamous cell carcinoma of the stomach: a case report.
  • Squamous cell carcinoma (SCC) originating from the stomach is a relatively rare entity.
  • Due to the advanced stage at the time of diagnosis in most of these cases, the prognosis is generally poor.
  • In the case presented here, dissemination of the tumor to the transverse colon, gallbladder and omentum was present at diagnosis.
  • Despite the tumor's advanced stage, complete remission was achieved after six courses of adjuvant chemotherapy with 5-flourouracil and cisplatin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Treatment Outcome


23. Grabenbauer GG, Kessler H, Matzel KE, Sauer R, Hohenberger W, Schneider IH: Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients. Dis Colon Rectum; 2005 Sep;48(9):1742-51
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.
  • PURPOSE: This study was designed to assess the long-term results following radiochemotherapy in patients with anal squamous-cell carcinoma and to evaluate the impact of tumor location on response, survival, and colostomy-free survival.
  • PATIENTS AND METHODS: Between 1985 and 2001, a total of 101 patients with anal carcinoma were registered for curative treatment, of whom 77 had involvement of the anal canal alone, 10 cases had extension into the perianal skin, and 14 patients had pure anal margin tumors.
  • Radiation treatment was directed to the primary tumor region and to the inguinal, perirectal, and internal iliac nodes using a three-field to four-field box technique with 10MV photons up to a total dose of 5040 cGy.
  • All patients were scheduled for simultaneous chemotherapy with two cycles of 5-fluorouracil at a dose of 1000 mg/m (2)/day as 120 hours of continuous intravenous infusion on Days 1 to 5 and 29 to 33 and mitomycin C at 10 mg/m (2)/day on Days 1 and 29.
  • Median follow-up time was was 7.5 (range, 1-16) years.
  • Following multivariate analysis, tumor location (anal canal vs. anal margin, P = 0.02), age (P = 0.003), and dose intensity of chemotherapy (< or =75 percent vs. >75 percent, P = 0.03) remained independent significant factors for overall survival.
  • CONCLUSIONS: With colostomy-free survival rates around 85 percent, long-term treatment results for anal canal carcinoma have reached a satisfactory level.
  • However, patients with larger lesions of the perianal skin are at high risk for locoregional recurrence and possible treatment intensification in this subgroup seems desirable.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991058.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK: Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum; 2008 Feb;51(2):147-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous-cell carcinoma of the anal canal: predictors of treatment outcome.
  • PURPOSE: The incidence of anal canal squamous-cell carcinoma is increasing.
  • Limited data exist on predictors of treatment failure.
  • This study was designed to identify predictors for relapse/persistence after first-line therapy.
  • METHODS: Using one database, we identified 131 Stages I-III patients treated for primary anal canal squamous-cell carcinoma at our institution from December 1986 to August 2006, with minimum six-month follow-up.
  • Demographic, pathologic, treatment, and outcome data were extracted.
  • Treatment failure was defined as biopsy-proven persistence or relapse (local and/or distant).
  • Although 114 (93.4 percent) completed radiotherapy, most required treatment breaks, making total duration of radiotherapy longer than planned.
  • Almost all patients undergoing radiotherapy (96.7 percent, 118/122) also had chemotherapy: 118 (100 percent, Stages I-III) had concurrent chemotherapy: (98 (83.8 percent) mitomycin/5-fluorouracil, 12 (10.2 percent) cisplatin/5-fluorouracil, 8 (6.8 percent) 5-fluorouracil alone); 35 of 46 (76 percent) Stage III patients received induction chemotherapy (34 (97.1 percent) cisplatin/5-fluorouracil, 1 (2.8 percent) 5-fluorouracil alone).
  • Thirty-seven patients (28.2 percent) failed first-line therapy.
  • Bivariate analyses demonstrated that T stage (P=0.0019), completion of radiotherapy, and total radiotherapy dose (P=0.03) were all significantly associated with treatment failure.
  • CONCLUSIONS: Tolerance of chemoradiation seems to be an important predictor of treatment success.
  • Effective therapies with less acute toxicity must be identified.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Combined Modality Therapy / methods. Disease-Free Survival. Endosonography. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. New York / epidemiology. Retrospective Studies. Survival Rate. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dis Colon Rectum. 2008 May;51(5):620
  • (PMID = 18180997.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Watanabe Y, Tsutsui M, Takeda S, Yoshino S, Oka M: [A case of esophageal cancer associated with colon cancer successfully treated with combination chemotherapy of FOLFOX and concurrent radiotherapy]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2439-41
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of esophageal cancer associated with colon cancer successfully treated with combination chemotherapy of FOLFOX and concurrent radiotherapy].
  • The standard chemotherapy regimen for esophageal cancer is cisplatin and 5-fluorouracil (5-FU).
  • We herein report a case of esophageal cancer associated with colon cancer, which was treated with combination chemotherapy of FOLFOX.
  • The patient received chemotherapy of modified FOLFOX6 (mFOLFOX6) at dosages of 80% of standard regimen (oxaliplatin 68 mg/m2, levofolinate calcium 160 mg/m2, bolus 5-FU 320 mg/m2, and followed by continuous 5-FU 1,920 mg/m2/ 46 hr) in combination with radiotherapy (total 61.6 Gy).
  • He developed grade 3 leukopenia after 2 courses of mFOLFOX6 and the 3rd course was started at dosages of 70% of standard regimen with 1 week delay.
  • Esophagogram revealed a partial response in primary tumor of the esophagus after 3 courses of chemotherapy with radiotherapy and blood chemistry examination showed negative squamous cell carcinoma antigen.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Colonic Neoplasms / therapy. Esophageal Neoplasms / therapy. Neoplasms, Multiple Primary / therapy
  • [MeSH-minor] Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Organoplatinum Compounds / administration & dosage

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037449.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


26. Azevedo CR, Cezana L, Moraes ES, Begnami MD, Paiva Júnior TF, Dettino AL, Fanelli MF: Synchronous thyroid and colon metastases from epidermoid carcinoma of the lung: case report. Sao Paulo Med J; 2010 Dec;128(6):371-4
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous thyroid and colon metastases from epidermoid carcinoma of the lung: case report.
  • CONTEXT: Non-small cell lung cancer (NSCLC) progresses to distant metastases in most cases.
  • CASE REPORT: We describe a case of squamous cell carcinoma in the lungs, with metastases in the colon and thyroid, in a 66-year-old female patient.
  • The lesion was unresectable and chemotherapy was started.
  • Biopsy and immunohistochemical analysis on the polyp showed that it was compatible with squamous cell carcinoma of pulmonary origin.
  • A aspiration biopsy and cellblock immunohistochemistry confirmed the squamous cell carcinoma of pulmonary origin.
  • After third-line chemotherapy, the patient progressed with acute obstructive abdomen due to a retroperitoneal mass.
  • Metastases to the thyroid and colon are rarely reported in cases of epidermoid carcinoma of the lungs.
  • Gastrointestinal involvement in pulmonary metastases may affect the stomach, small intestine and colon, and cases of bleeding and perforation have already been reported.
  • We did not find any previous reports in the literature, on lung cancer with metastases concomitantly in the colon and thyroid, in a single patient.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Colonic Neoplasms / secondary. Lung Neoplasms / pathology. Thyroid Neoplasms / secondary

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308162.001).
  • [ISSN] 1806-9460
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


27. Rasheed S, Yap T, Zia A, McDonald PJ, Glynne-Jones R: Chemo-radiotherapy: an alternative to surgery for squamous cell carcinoma of the rectum--report of six patients and literature review. Colorectal Dis; 2009 Feb;11(2):191-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemo-radiotherapy: an alternative to surgery for squamous cell carcinoma of the rectum--report of six patients and literature review.
  • PURPOSE: Since 1943 [1], only 45 patients of squamous cancer of the rectum have been reported in the published reports and the largest series to date consists of 12 patients.
  • Reports suggest that the primary treatment is surgical resection but, in the light of nonsurgical advances in the treatment of anal squamous cell carcinoma (SCC), we present a review of the literature and report six patients treated by chemoradiation therapy (CRT).
  • METHOD: A literature search was undertaken using the keywords squamous cell, epidermoid, basaloid and cloacagenic and cancer of rectum and colon to provide evidence for this discussion from studies of surgery, radiation therapy and CRT in rectal SCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Radiotherapy / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18462236.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 40
  •  go-up   go-down


28. Shariat-Torbaghan S, Emami-Aleagha M, Sedighi S, Azadbakht F, Keshvari A, Hajarizadeh B, Rosai J: Squamous cell carcinoma arising in an ovarian mature cystic teratoma: a case report. Arch Iran Med; 2009 Mar;12(2):186-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma arising in an ovarian mature cystic teratoma: a case report.
  • The most common malignancy is squamous cell carcinoma, which consists of about 75% of malignant transformations.
  • In the present report, we describe a case of advanced-stage squamous cell carcinoma arising in a mature cystic teratoma.
  • A postmenopausal 63-year-old woman with squamous cell carcinoma arising in a mature cystic teratoma is presented.
  • Histopatholog was compatible with squamous cell carcinoma arising in a mature cystic teratoma.
  • After a few episodes of intestinal obstruction and colostomy, she underwent partial resection of the ileum and sigmoid colon four months after the initial oophorectomy.
  • Histopathologic study showed metastatic poorly-differentiated squamous cell carcinoma.
  • Subsequently, she underwent two courses of combination chemotherapy with cisplatin, leucovorin, and 5-fluorouracil with no response.
  • [MeSH-major] Carcinoma, Squamous Cell / ultrasonography. Neoplasms, Multiple Primary / ultrasonography. Ovarian Neoplasms / ultrasonography. Teratoma / ultrasonography
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Colostomy. Fatal Outcome. Female. Fluorouracil / therapeutic use. Humans. Ileal Neoplasms / complications. Ileal Neoplasms / secondary. Ileal Neoplasms / therapy. Intestinal Obstruction / etiology. Intestinal Obstruction / surgery. Leucovorin / therapeutic use. Middle Aged. Ovariectomy. Sigmoid Neoplasms / complications. Sigmoid Neoplasms / secondary. Sigmoid Neoplasms / therapy. Vitamin B Complex / therapeutic use

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249893.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 12001-76-2 / Vitamin B Complex; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


29. Stadler RF, Gregorcyk SG, Euhus DM, Place RJ, Huber PJ, Simmang CL: Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy. Dis Colon Rectum; 2004 Aug;47(8):1305-9
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy.
  • PURPOSE: Before the development of highly active antiretroviral therapy for the treatment of HIV infection, HIV patients diagnosed with invasive squamous-cell carcinoma of the anal canal carried a very poor prognosis.
  • This study was designed to determine the outcome in a similar group of patients in the era of highly active antiretroviral therapy.
  • METHODS: HIV-positive patients treated for invasive squamous-cell carcinoma of the anal canal at the University of Texas Medical Center affiliated hospitals from 1980 to 2001 were identified from operative data and cancer registries.
  • We reviewed these records and collected data regarding age, CD4 count, highly active antiretroviral therapy, cancer treatment, complications, and survival.
  • The patients were divided into two groups based on the presence or absence of highly active antiretroviral therapy and compared using a Kaplan-Meier approach.
  • RESULTS: Fourteen patients with HIV and invasive squamous-cell carcinoma of the anal canal were identified.
  • Six were in the prehighly active antiretroviral therapy group and eight in the highly active antiretroviral therapy group.
  • All were considered for treatment with chemotherapy and radiation.
  • In the prehighly active antiretroviral therapy group, one patient refused therapy and three were unable to complete the squamous-cell carcinoma therapy as planned because of complications.
  • Four of eight highly active antiretroviral therapy patients were unable to complete the squamous-cell carcinoma therapy as planned.
  • The prehighly active antiretroviral therapy patients had a mean age of 40 years and a mean CD4 count of 190 at the time of diagnosis.
  • The highly active antiretroviral therapy patients had a mean age of 44 years and a mean CD4 count of 255 at the time of diagnosis.
  • The 24-month survival was 17 percent in the prehighly active antiretroviral therapy group and 67 percent in the highly active antiretroviral therapy group (P = 0.0524).
  • All six patients in the prehighly active antiretroviral therapy group died with active squamous-cell carcinoma vs. two in the highly active antiretroviral therapy group.
  • Four of the remaining six patients had no evidence of active squamous-cell carcinoma at the last follow-up visit.
  • CONCLUSIONS: A review of patients with HIV and invasive squamous-cell carcinoma of the anal canal suggests a trend toward a higher CD4 count at the time of diagnosis and improved survival in patients receiving highly active antiretroviral therapy.
  • In this new era, HIV-positive patients should be on highly active antiretroviral therapy.
  • If not, highly active antiretroviral therapy should be initiated, and standard multimodality therapies for invasive squamous-cell carcinoma of the anal canal are recommended.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / pathology. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. HIV Infections / complications
  • [MeSH-minor] Adult. CD4 Lymphocyte Count. Combined Modality Therapy. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome


30. Srivastava K, Singh S, Srivastava M, Srivastava AN: Incisional skin metastasis of a squamous cell cervical carcinoma 3.5 years after radical treatment--a case report. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1183-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incisional skin metastasis of a squamous cell cervical carcinoma 3.5 years after radical treatment--a case report.
  • Metastatic carcinoma in an abdominal wall incision from internal malignant neoplasm is an uncommon and often a preterminal event.
  • Most commonly metastatic skin incisional cancers have been reported with cancers of colon, kidney, and bladder.
  • Incisional metastasis from postoperative case of carcinoma cervix is very rare.
  • We report a postoperative case of squamous cell carcinoma cervix FIGO stage IIA in a patient who after 3.5 years of completion of radical treatment (postoperative external and intravaginal radiation therapy) developed incisional skin metastasis followed by extensive subcutaneous metastasis in the vulval region.
  • She received salvage chemotherapy; however, she did not show any response and finally succumbed to the disease.
  • The intent of treatment remains palliation either by radiation/chemotherapy/surgery alone or in combinations.
  • As far as we know, this is the first case of squamous cell carcinoma cervix stage IIA having incisional scar recurrence 3.5 years after postoperative radiotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Neoplasm Recurrence, Local / drug therapy. Skin Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Fatal Outcome. Female. Fluorouracil / administration & dosage. Gynecologic Surgical Procedures. Humans. Radiotherapy


31. Sato H, Kuroda M, Maruta M, Maeda K, Koide Y: Mucoepidermoid carcinoma of the ascending colon: report of a case. Surg Today; 2002;32(11):1004-7
Genetic Alliance. consumer health - Mucoepidermoid carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of the ascending colon: report of a case.
  • Mucoepidermoid carcinoma of the gastrointestinal tract is a rare entity.
  • The present case is the first report of mucoepidermoid carcinoma in the large bowel.
  • An ulcerating tumor was thus identified in the ascending colon.
  • The tumor consisted of PAS-positive mucin-producing cells, epidermoid cells, and intermediate cells.
  • No differentiated squamous cell carcinoma cells were identified in any part of the tumor.
  • The tumor was diagnosed as a mucoepidermoid carcinoma of the ascending colon.
  • Unfortunately, despite chemotherapy, the patient developed liver metastases and died of liver failure 10 months postoperatively.
  • [MeSH-major] Carcinoma, Mucoepidermoid / surgery. Colonic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12444441.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Gaud U, Goyal T, Shukla M, Kumar V, Pandey M: Synchronous occurrence of adenocarcinoma of the rectum with squamous cell carcinoma of a retrorectal cyst: report of a case and review of the literature. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous occurrence of adenocarcinoma of the rectum with squamous cell carcinoma of a retrorectal cyst: report of a case and review of the literature.
  • We report here the case of a middle-aged man who had synchronous presentation of adenocarcinoma of the rectum and squamous cell carcinoma in a retrorectal cyst.
  • Postoperative histopathological examination showed adenocarcinoma of the rectum and squamous cell carcinoma of the cyst.
  • The patient received adjuvant chemotherapy and after 18 months of follow-up is free of any local or metastatic disease.
  • Synchronous occurrence of rectal cancer with carcinoma in a retrorectal cyst has not been previously reported in the literature in English.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann R Coll Surg Engl. 2000 Mar;82(2):146 [10743441.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jun;170(6):1488-90 [9609159.001]
  • [Cites] Radiographics. 2001 May-Jun;21(3):575-84 [11353107.001]
  • [Cites] Clin Radiol. 1992 Apr;45(4):288-9 [1395393.001]
  • [Cites] Am Surg. 2004 Nov;70(11):1007-9 [15586516.001]
  • [Cites] Histol Histopathol. 2005 Oct;20(4):1065-9 [16136488.001]
  • [Cites] Ann R Coll Surg Engl. 2005 Sep;87(5):W8-10 [16176703.001]
  • [Cites] World J Gastroenterol. 2005 Oct 21;11(39):6225-7 [16273657.001]
  • [Cites] Br J Surg. 1986 May;73(5):377 [3708289.001]
  • [Cites] Crit Rev Diagn Imaging. 1984;21(4):307-74 [6428808.001]
  • [Cites] Can J Surg. 1981 Jul;24(4):351-2 [7272850.001]
  • [Cites] J Clin Pathol. 1999 Apr;52(4):310-2 [10474528.001]
  • [Cites] Ann R Coll Surg Engl. 1999 May;81(3):205-6 [10364957.001]
  • [Cites] Am Surg. 1995 Nov;61(11):997-1000 [7486435.001]
  • [Cites] Br J Radiol. 1999 Sep;72(861):896-8 [10645197.001]
  • [Cites] Am J Gastroenterol. 2000 May;95(5):1344-7 [10811351.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):447 [11289294.001]
  • [Cites] J Pediatr Surg. 1990 Sep;25(9):980-4 [2213451.001]
  • [Cites] J R Soc Med. 1979 Dec;72(12):935-7 [233246.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):725-9 [10782156.001]
  • (PMID = 21686338.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027582
  •  go-up   go-down


33. Melcher AA, Sebag-Montefiore D: Concurrent chemoradiotherapy for squamous cell carcinoma of the anus using a shrinking field radiotherapy technique without a boost. Br J Cancer; 2003 May 6;88(9):1352-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent chemoradiotherapy for squamous cell carcinoma of the anus using a shrinking field radiotherapy technique without a boost.
  • Chemoradiotherapy (CRT) is now widely accepted as the primary treatment modality for squamous cell cancer of the anus.
  • While randomised trials have clearly shown CRT to be more effective than radiotherapy alone, there remains uncertainty over the optimal integration of chemotherapy and radiation.
  • Chemotherapy comprised mitomycin C (MMC) (day 1) and 5-fluorouracil (5-FU) (days 1-4, and 29-32), concurrent with 50 Gy in 25 fractions radiation, using a two-phase shrinking field technique.
  • These results are comparable with those from large randomised studies, and suggest that a two-phase shrinking field radiotherapy technique with no boost, concurrent with MMC/5-FU chemotherapy, is an effective regimen for this disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Neoplasms, Squamous Cell / drug therapy. Neoplasms, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Staging. Radiotherapy / methods. Radiotherapy Dosage. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Oncol (R Coll Radiol). 2001;13(2):130-4 [11373876.001]
  • [Cites] Br J Cancer. 1999 Jul;80(10):1588-94 [10408404.001]
  • [Cites] Radiother Oncol. 2001 Oct;61(1):15-22 [11578724.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1167-74 [11870157.001]
  • [Cites] Clin Sci. 1969 Aug;37(1):169-80 [4980763.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] Cancer. 1983 May 15;51(10):1826-9 [6831348.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] J R Soc Med. 1991 Jul;84(7):389-90 [1865441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Am J Clin Oncol. 1995 Feb;18(1):32-9 [7847256.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1995;7(2):123-6 [7619762.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] J Surg Oncol. 1999 Feb;70(2):71-7 [10084647.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):675-80 [11395235.001]
  • (PMID = 12778060.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2741046
  •  go-up   go-down


34. Hirasaki S, Suzuki S, Umemura S, Kamei H, Okuda M, Kudo K: Asymptomatic colonic metastases from primary squamous cell carcinoma of the lung with a positive fecal occult blood test. World J Gastroenterol; 2008 Sep 21;14(35):5481-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymptomatic colonic metastases from primary squamous cell carcinoma of the lung with a positive fecal occult blood test.
  • We describe a 74-year-old man with a colonic metastatic squamous cell carcinoma (SCC) from the lung.
  • Computed tomography (CT) of the chest demonstrated a large lung tumor in the right upper lobe obstructing the right upper bronchus.
  • Bronchoscopy revealed an easy-bleeding tumor in the right upper bronchus that was diagnosed as poorly differentiated squamous cell lung carcinoma.
  • Colonoscopy revealed a large protruding lesion with central ulceration in the descending colon.
  • Histological examination of the biopsy specimen obtained from the colonic lesion revealed SCC.
  • The lesion was diagnosed as metastatic colonic SCC.
  • He underwent chemotherapy with an infusion of cisplatin 130 mg i.v. day 1, and docetaxel hydrate 100 mg i.v. day 1, repeated every 4 wk, followed by 4 courses of chemotherapy.
  • The primary lesion shrank by less than 10% and was judged to be "Partial Response" (PR) after 3 courses of treatment.
  • The patient still lived 23 wk after the diagnosis of metastatic colonic SCC.
  • Colonic metastasis of primary SCC of the lung is rare.
  • [MeSH-major] Carcinoma, Small Cell / secondary. Colonic Neoplasms / secondary. Lung Neoplasms

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1980 Dec;74(6):504-6 [6259933.001]
  • [Cites] J Postgrad Med. 2002 Jul-Sep;48(3):199-200 [12432195.001]
  • [Cites] Cancer. 1987 Apr 15;59(8):1486-9 [3028602.001]
  • [Cites] J Surg Oncol. 1992 Dec;51(4):287-91 [1434663.001]
  • [Cites] Br J Clin Pract. 1993 Sep-Oct;47(5):276-7 [8292483.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1996 Sep;34(9):968-72 [8937139.001]
  • [Cites] Tuberk Toraks. 2005;53(3):280-3 [16258889.001]
  • [Cites] Kyobu Geka. 2006 May;59(5):426-9 [16715897.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4939-40 [17050879.001]
  • [Cites] Lung Cancer. 2006 Dec;54(3):319-23 [17010474.001]
  • [Cites] J Thorac Oncol. 2007 Feb;2(2):115-20 [17410025.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Feb;135(2):297-301 [18512073.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 May;19(5):719-20 [11343961.001]
  • [Cites] Acta Chir Belg. 2001 Nov-Dec;101(6):300-3 [11868507.001]
  • [Cites] Cancer. 1982 Jan 1;49(1):170-2 [6274500.001]
  • (PMID = 18803365.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2744902
  •  go-up   go-down


35. Li Q, Gao C, Juzi JT, Hao X: Analysis of 82 cases of retroperitoneal schwannoma. ANZ J Surg; 2007 Apr;77(4):237-40
Genetic Alliance. consumer health - Schwannoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of the study was to improve the diagnosis and treatment of retroperitoneal schwannoma by analysing clinical manifestations and postoperative course of this rare disease.
  • Only in 13 patients (15.9%) a correct preoperative diagnosis was made by either ultrasound-guided biopsy, computed tomography scanning or magnetic resonance imaging.
  • All patients received operative therapy.
  • Two patients (2.4%) had multiple schwannomas and two others had a simultaneous malignancy (adenocarcinoma of the ascending colon and squamous-cell carcinoma of the lung, respectively).
  • However, with the preoperative assessment of ultrasound-guided fine-needle aspiration, computed tomography and magnetic resonance imaging, the accuracy of diagnosis could definitely be improved.
  • Treatment depends solely on surgery.
  • Malignant schwannomas are insensitive to chemotherapy and radiation, resulting in poor prognosis.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Diagnostic Imaging. Female. Humans. Infant. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17388825.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


36. Handisurya A, Rieger A, Bago-Horvath Z, Schellenbacher C, Bankier A, Salat A, Stingl G, Kirnbauer R: Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient. Sex Transm Infect; 2009 Aug;85(4):261-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient.
  • BACKGROUND: Buschke-Löwenstein tumour (BLT) of the anogenitalia is a locally invasive, destructively growing verrucous carcinoma that does not metastasise.
  • Nevertheless, the tumour grows relentlessly and may rarely progress into squamous cell cancer (SCC).
  • RESULTS: A human immunodeficiency virus (HIV)-infected immunosuppressed patient developed (peri)anal warts accompanied by recurrent abscesses and fistulae.
  • Histology revealed condylomata acuminata, and low-risk genital human papillomavirus (HPV) type 11b was detected.
  • Whereas highly active antiretroviral therapy (HAART) effectively suppressed HIV replication, radiochemotherapy plus anti-EGFR antibody did not halt tumour progression, and the patient died from tumour-cachexia.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / secondary. HIV Infections / complications. Immunocompromised Host
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / virology. Anti-HIV Agents / therapeutic use. Cachexia / etiology. Fatal Outcome. Groin. HIV Seropositivity / drug therapy. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness


37. Wang L, Xue L, Yan H, Li J, Lu Y: Effects of ROCK inhibitor, Y-27632, on adhesion and mobility in esophageal squamous cell cancer cells. Mol Biol Rep; 2010 Apr;37(4):1971-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of ROCK inhibitor, Y-27632, on adhesion and mobility in esophageal squamous cell cancer cells.
  • Rho-associated protein kinase (ROCK), a molecular switch, modulates cellular functions in many cancers, such as hepatocellular, breast, colon cancers, etc.
  • However, little is known the effect of ROCK on cell adhesion and mobility in esophageal squamous cell cancer (ESCC), one of the most diagnosed cancers in China.
  • Motility of ESCC cells changes were examined by detection of phosphorylated cofilin and observed under confocal microscopy, respectively.
  • All these findings indicate that ROCK signaling pathway plays an important role in cell adhesion and mobility, suggesting that it may be used as a potential target for therapy of ESCC.
  • [MeSH-major] Amides / pharmacology. Carcinoma, Squamous Cell / pathology. Cell Movement / drug effects. Esophageal Neoplasms / pathology. Protein Kinase Inhibitors / pharmacology. Pyridines / pharmacology. rho-Associated Kinases / antagonists & inhibitors
  • [MeSH-minor] Cell Adhesion / drug effects. Cell Line, Tumor. Humans

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatol Res. 2008 Aug;38(8):810-7 [18507693.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Jul;295(1):C38-49 [18463228.001]
  • [Cites] Exp Cell Res. 2008 Oct 15;314(17):3162-74 [18694745.001]
  • [Cites] Mol Cancer Res. 2008 Sep;6(9):1410-20 [18819929.001]
  • [Cites] World J Gastroenterol. 2008 May 21;14(19):3054-8 [18494058.001]
  • [Cites] J Craniomaxillofac Surg. 2007 Jan;35(1):1-9 [17296306.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5549-57 [18055804.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Oct;291(4):C668-77 [16641163.001]
  • [Cites] Am J Respir Cell Mol Biol. 1999 Jun;20(6):1190-200 [10340938.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3317-25 [12882776.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1056:405-12 [16387705.001]
  • [Cites] J Biol Chem. 2009 May 29;284(22):15147-57 [19293150.001]
  • [Cites] Int J Oncol. 2008 Sep;33(3):585-93 [18695890.001]
  • [Cites] Int J Cancer. 1996 Jun 21;69(3):225-35 [8682592.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Dec;327(3):777-88 [18791066.001]
  • [Cites] World J Gastroenterol. 2008 Oct 7;14(37):5665-73 [18837082.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2006 May;38(5):318-26 [16680372.001]
  • [Cites] Neoplasia. 2008 Dec;10(12):1444-58 [19048123.001]
  • [Cites] Jpn J Cancer Res. 2000 Aug;91(8):811-6 [10965022.001]
  • [Cites] J Cell Biol. 2008 Nov 17;183(4):697-710 [19015318.001]
  • [Cites] Cancer Lett. 2009 Nov 1;284(2):122-30 [19303207.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11305-10 [18685096.001]
  • [Cites] Cancer Lett. 2007 Aug 18;253(2):236-48 [17360108.001]
  • [Cites] Gut. 2009 Aug;58(8):1121-7 [19398441.001]
  • [Cites] Biol Pharm Bull. 2008 Sep;31(9):1802-5 [18758081.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1500-9 [16565385.001]
  • [Cites] Trends Cell Biol. 2005 Mar;15(3):138-45 [15752977.001]
  • [Cites] J Pineal Res. 2009 Jan;46(1):15-21 [18482340.001]
  • [Cites] Kobe J Med Sci. 2007;53(3):125-34 [17684444.001]
  • [Cites] Mol Cancer Res. 2005 Aug;3(8):425-33 [16123138.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Histopathology. 2008 Apr;52(5):560-8 [18312357.001]
  • [Cites] J Biol Chem. 2006 Oct 6;281(40):29614-24 [16882662.001]
  • [Cites] Lab Invest. 2007 Nov;87(11):1149-58 [17876296.001]
  • [Cites] Cancer Lett. 2005 Jan 31;218(1):69-79 [15639342.001]
  • (PMID = 19649725.001).
  • [ISSN] 1573-4978
  • [Journal-full-title] Molecular biology reports
  • [ISO-abbreviation] Mol. Biol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Amides; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 138381-45-0 / Y 27632; EC 2.7.11.1 / rho-Associated Kinases
  •  go-up   go-down


38. Jung TS, Oh YL, Min YK, Lee MS, Lee MK, Kim KW, Chung JH: A patient with primary squamous cell carcinoma of the thyroid intermingled with follicular thyroid carcinoma that remains alive more than 8 years after diagnosis. Korean J Intern Med; 2006 Mar;21(1):73-8
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with primary squamous cell carcinoma of the thyroid intermingled with follicular thyroid carcinoma that remains alive more than 8 years after diagnosis.
  • Primary squamous cell carcinoma of the thyroid is an extremely rare tumor with a highly aggressive clinical course.
  • We report here on a patient with primary squamous cell carcinoma of the thyroid who remains alive more than 8 years after diagnosis.
  • Histopathologic findings revealed primary squamous cell carcinoma combined with follicular carcinoma of the thyroid.
  • TSH suppressive therapy with L-thyroxine was administered alone rather than radioactive iodine therapy or chemotherapy.
  • The patient underwent colectomy for the diagnosis of a colon cancer.
  • Recent evaluation has revealed a new lesion in the lung; this was diagnosed as metastatic follicular carcinoma originating from the thyroid.
  • High dose radioactive iodine therapy was administered, and he remains alive in stable condition.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Squamous Cell / pathology. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 1999 Dec;25(6):606-9 [10556008.001]
  • [Cites] Ann Surg. 1960 Apr;151:551-61 [13820008.001]
  • [Cites] Histopathology. 2001 Sep;39(3):279-86 [11532039.001]
  • [Cites] Diagn Cytopathol. 2002 Oct;27(4):227-31 [12357501.001]
  • [Cites] Int Surg. 1968 Dec;50(6):538-41 [5698652.001]
  • [Cites] Am J Clin Pathol. 1971 Jan;55(1):93-8 [5099785.001]
  • [Cites] J Surg Oncol. 1977;9(6):567-78 [338999.001]
  • [Cites] Am J Surg Pathol. 1978 Jun;2(2):133-40 [655339.001]
  • [Cites] Cancer. 1980 Oct 15;46(8):1833-42 [7427886.001]
  • [Cites] J Surg Oncol. 1982 Jan;19(1):36-43 [7057643.001]
  • [Cites] Head Neck Surg. 1984 Jul-Aug;6(6):1035-42 [6469655.001]
  • [Cites] Can Med Assoc J. 1985 Apr 15;132(8):925-31 [3978516.001]
  • [Cites] World J Surg. 1985 Feb;9(1):128-35 [3984364.001]
  • [Cites] Cell Tissue Res. 1985;242(1):211-5 [3899366.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1988;412(4):357-63 [3125674.001]
  • [Cites] Am J Surg. 1988 Jul;156(1):44-6 [3394892.001]
  • [Cites] J Pathol. 1988 Jul;155(3):191-200 [3045277.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1989 Jan;98(1 Pt 1):59-65 [2910191.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4744-9 [8062273.001]
  • [Cites] Head Neck. 1994 Nov-Dec;16(6):582-5 [7822183.001]
  • [Cites] APMIS. 1996 Jun;104(6):419-23 [8774670.001]
  • [Cites] Virchows Arch. 1997 Mar;430(3):239-45 [9099982.001]
  • [Cites] Mil Surg. 1951 Oct;109(4):406-14 [14874967.001]
  • [Cites] Cancer. 1952 Sep;5(5):966-74 [12988185.001]
  • [Cites] Am Surg. 1964 Apr;30:247-52 [14149689.001]
  • [Cites] Ann Surg. 1964 Aug;160:169-77 [14209716.001]
  • [Cites] Cancer. 1956 Mar-Apr;9(2):306-9 [13304848.001]
  • [Cites] Hum Pathol. 2000 Sep;31(9):1139-45 [11014583.001]
  • (PMID = 16646570.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3891069
  •  go-up   go-down


39. Theodosopoulos TK, Marinis AD, Dafnios NA, Vassiliou JG, Samanides LD, Carvounis EE, Smyrniotis VE: Aggressive treatment of metastatic squamous cell carcinoma of the rectum to the liver: a case report and a brief review of the literature. World J Surg Oncol; 2006;4:49
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive treatment of metastatic squamous cell carcinoma of the rectum to the liver: a case report and a brief review of the literature.
  • BACKGROUND: Rectal squamous cell carcinoma (SCC) is a rare tumor.
  • In this study we report a rectal metastatic SCC to the liver, discussing the efficacy of aggressive adjuvant and neo-adjuvant therapies on survival and prognosis.
  • Five months after the initial operation liver metastasis was demonstrated and a liver resection was carried out, followed by adjuvant chemotherapy.
  • CONCLUSION: Although prognosis of rectal SCC is worse than that of adenocarcinoma, an aggressive therapeutic approach with surgery as the primary treatment, followed by combined neo- and adjuvant chemo-radiotherapy, may be necessary in order to improve survival and prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1999 Jan;42(1):102-9 [10211528.001]
  • [Cites] Rev Invest Clin. 1996 Nov-Dec;48(6):453-6 [9028152.001]
  • [Cites] Eur J Surg Oncol. 2002 Sep;28(6):657-60 [12359204.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1535-40 [12432303.001]
  • [Cites] Clin Colorectal Cancer. 2001 May;1(1):55-8 [12445380.001]
  • [Cites] Clin Colorectal Cancer. 2002 Feb;1(4):243-8 [12450423.001]
  • [Cites] Am J Gastroenterol. 1962 Jan;37:48-54 [14006818.001]
  • [Cites] Int J Colorectal Dis. 1992 Sep;7(3):144-7 [1402312.001]
  • [Cites] APMIS. 1988 Sep;96(9):839-44 [3166810.001]
  • [Cites] Dis Colon Rectum. 1988 Mar;31(3):228-35 [3280272.001]
  • [Cites] Dis Colon Rectum. 1988 Apr;31(4):323-6 [3282843.001]
  • [Cites] Indian J Pathol Microbiol. 1987 Jan;30(1):45-50 [3315994.001]
  • [Cites] J Surg Oncol. 1987 Jun;35(2):117-9 [3586681.001]
  • [Cites] Eur J Surg Oncol. 1987 Oct;13(5):455-8 [3666162.001]
  • [Cites] Dis Colon Rectum. 1985 Dec;28(12):967-72 [4064861.001]
  • [Cites] Cancer. 1971 Nov;28(5):1111-7 [5125659.001]
  • [Cites] J Pathol. 1979 Nov;129(3):139-47 [529012.001]
  • [Cites] Am J Surg Pathol. 1978 Mar;2(1):47-54 [637188.001]
  • [Cites] Vopr Onkol. 1984;30(8):76-83 [6485288.001]
  • [Cites] Dis Colon Rectum. 1983 Mar;26(3):188-91 [6825528.001]
  • [Cites] Dis Colon Rectum. 1996 Nov;39(11):1265-8 [8918436.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):341-6 [11289278.001]
  • (PMID = 16895595.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1555584
  •  go-up   go-down


40. Mathonnet M, Fermeaux V: [Colon cancer in pregnancy]. J Chir (Paris); 2003 Sep;140(4):221-4
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colon cancer in pregnancy].
  • Colon cancers arise only rarely in the course of a pregnancy.
  • Yet colon obstruction, perforation and metastatic spread seem to occur more frequently in this setting than with the average colon cancer.
  • No case of epidermoid (squamous cell) cancer of the colon has been previously described in a pregnant woman.
  • This conjunction has a catastrophic prognosis: the diagnosis of colon tumor is delayed since symptoms are masked by the pregnancy, and epidermoid colon cancer is a particularly aggressive lesion.
  • A major sub-diaphragmatic surgical procedure can be performed with reasonable safety to mother and fetus.
  • Neo-adjuvant chemotherapy can be administered although the risks to the fetus are not well known.
  • During the first trimester, a therapeutic abortion can be proposed to optimise the treatment of the mother.
  • During the second and third trimesters, treatment of the mother exposes the fetus to the risk of malformations or premature delivery; delay in maternal treatment in hopes of prolonging the pregnancy in order to obtain a viable neonate diminish the chances of maternal survival.
  • [MeSH-major] Carcinoma, Squamous Cell. Colonic Neoplasms. Pregnancy Complications, Neoplastic
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cesarean Section. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Diseases in Twins. Down Syndrome. Fatal Outcome. Female. Fetal Death. Fluorouracil / administration & dosage. Humans. Intestinal Perforation / etiology. Leucovorin / administration & dosage. Liver Neoplasms / secondary. Male. Organoplatinum Compounds / administration & dosage. Pregnancy. Pregnancy, Multiple

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 13679771.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; FOLFOX2-3 regimen
  • [Number-of-references] 20
  •  go-up   go-down


41. Katori H, Baba Y, Imagawa Y, Nishimura G, Kagesato Y, Takagi E, Ishii A, Yanoma S, Maekawa R, Yoshioka T, Nagashima Y, Kato Y, Tsukuda M: Reduction of in vivo tumor growth by MMI-166, a selective matrix metalloproteinase inhibitor, through inhibition of tumor angiogenesis in squamous cell carcinoma cell lines of head and neck. Cancer Lett; 2002 Apr 25;178(2):151-9
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction of in vivo tumor growth by MMI-166, a selective matrix metalloproteinase inhibitor, through inhibition of tumor angiogenesis in squamous cell carcinoma cell lines of head and neck.
  • We have recently shown that MMI-166, a new orally active MMP inhibitor specific for MMP-2 and -9, suppressed experimental metastasis of Lewis lung cancer, C-H1 human colon cancer, and pancreatic cancer without affecting tumor growth in vitro.
  • In the present study, we determined whether oral administration of MMI-166 reduces tumor growth not only in such tumors but also in squamous cell carcinoma of head and neck (SCCHN).
  • Therefore, MMI-166 seems to be useful for tumor dormancy therapy of SCCHN.
  • [MeSH-major] Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / drug therapy. Enzyme Inhibitors / pharmacology. Head and Neck Neoplasms / blood supply. Head and Neck Neoplasms / drug therapy. Neovascularization, Pathologic / drug therapy. Sulfonamides / pharmacology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11867199.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Matrix Metalloproteinase Inhibitors; 0 / N-alpha-(4-(2-phenyl-2H- tetrazole-5-yl) phenyl sulfonyl)-D-tryptophan; 0 / Sulfonamides
  •  go-up   go-down


42. Hanessian S, Saavedra OM, Xie F, Amboldi N, Battistini C: Design and synthesis of functionalized glycomers as non-peptidic ligands for SH2 binding and as inhibitors of A-431 human epidermoid and HT-29 colon carcinoma cell lines. Bioorg Med Chem Lett; 2000 Mar 6;10(5):439-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Design and synthesis of functionalized glycomers as non-peptidic ligands for SH2 binding and as inhibitors of A-431 human epidermoid and HT-29 colon carcinoma cell lines.
  • A set of O-substituted aryl beta-D-glucopyranosides were prepared and found to have inhibitory activity on the growth of two carcinoma cell lines.
  • [MeSH-major] Antineoplastic Agents / chemical synthesis. Glucosides / chemical synthesis. src Homology Domains / drug effects
  • [MeSH-minor] Carcinoma, Squamous Cell / drug therapy. HT29 Cells. Humans. Ligands. Molecular Conformation. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10743943.001).
  • [ISSN] 0960-894X
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glucosides; 0 / Ligands
  •  go-up   go-down


43. Desnoyers LR, Pai R, Ferrando RE, Hötzel K, Le T, Ross J, Carano R, D'Souza A, Qing J, Mohtashemi I, Ashkenazi A, French DM: Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene; 2008 Jan 3;27(1):85-97
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.
  • Here we report that FGF19 and its cognate receptor FGF receptor 4 (FGFR4) are coexpressed in primary human liver, lung and colon tumors and in a subset of human colon cancer cell lines.
  • To test the importance of FGF19 for tumor growth, we developed an anti-FGF19 monoclonal antibody that selectively blocks the interaction of FGF19 with FGFR4.
  • This antibody abolished FGF19-mediated activity in vitro and inhibited growth of colon tumor xenografts in vivo and effectively prevented hepatocellular carcinomas in FGF19 transgenic mice.
  • These findings suggest that the inactivation of FGF19 could be beneficial for the treatment of colon cancer, liver cancer and other malignancies involving interaction of FGF19 and FGFR4.
  • [MeSH-major] Antibodies, Blocking / therapeutic use. Antineoplastic Agents / pharmacology. Carcinoma, Hepatocellular / drug therapy. Colonic Neoplasms / drug therapy. Fibroblast Growth Factors / antagonists & inhibitors. Gene Targeting / methods. Liver Neoplasms, Experimental / drug therapy. Xenograft Model Antitumor Assays / methods
  • [MeSH-minor] Animals. Antibodies, Monoclonal / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / immunology. Carcinoma, Squamous Cell / metabolism. HCT116 Cells. HT29 Cells. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / genetics. Lung Neoplasms / immunology. Mice. Mice, Inbred BALB C. Mice, Nude. Mice, Transgenic. Neoplasm Transplantation. Receptor, Fibroblast Growth Factor, Type 4 / biosynthesis. Receptor, Fibroblast Growth Factor, Type 4 / genetics. Receptor, Fibroblast Growth Factor, Type 4 / metabolism. Transplantation, Heterologous

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17599042.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Blocking; 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / FGF19 protein, human; 62031-54-3 / Fibroblast Growth Factors; EC 2.7.10.1 / FGFR4 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 4
  •  go-up   go-down


44. Sengoz M, Abacioglu U, Salepci T, Eren F, Yumuk F, Turhal S: Extrapulmonary small cell carcinoma: multimodality treatment results. Tumori; 2003 May-Jun;89(3):274-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrapulmonary small cell carcinoma: multimodality treatment results.
  • AIMS AND BACKGROUND: Extrapulmonary small cell carcinoma is a distinct entity that can occur in many sites, and it is pathologically similar to small-cell lung cancer.
  • We report the results of a retrospective study of a multimodality treatment of 16 consecutive patients with a diagnosis of extrapulmonary small-cell carcinoma.
  • METHODS: Primary tumor site was prostate in 2, gallbladder in 2, uterine cervix in 2, liver in 2, endometrium in 1, epididymis in 1, colon in 1, larynx in 1, breast in 1, and unknown primary tumor in 3 patients.
  • Histologically, 14 were pure extrapulmonary small-cell carcinoma and 2 were mixed with squamous-cell carcinoma.
  • All patients, except the one with a breast primary, were treated with chemotherapy (mostly platinum-based regimens).
  • CONCLUSIONS: Treatment results for extrapulmonary small-cell carcinoma are comparable to those of small-cell carcinomas of the lung.
  • [MeSH-major] Carcinoma, Small Cell / therapy. Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12908782.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Singhal SS, Singhal J, Yadav S, Dwivedi S, Boor PJ, Awasthi YC, Awasthi S: Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1). Cancer Res; 2007 May 01;67(9):4382-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1).
  • In the absence of chemotherapy, depletion or inhibition of RALBP1 causes regression of syngeneic mouse B16 melanoma.
  • Because RALBP1 transports anthracycline and Vinca alkaloid drugs, as well as GS-E, and because it confers resistance to these drugs, we proposed that depletion or inhibition of RALBP1 should cause regression of human solid tumors that overexpress RALBP1 and augment chemotherapy efficacy.
  • Non-small-cell lung cancer (NSCLC) H358 and H520 and colon SW480 cell lines were used.
  • Cytotoxic synergy between anti-RALBP1 immunoglobulin G (IgG), cis-diammine-dichloroplatinum (II) [CDDP], and vinorelbine was examined in cell culture and xenografts of NSCLC cells.
  • Effects of RALBP1 depletion by antisense were examined in xenografts of NSCLC H358, NSCLC H520, and colon SW480 cells.
  • RALBP1 depletion by phosphorothioate antisense was confirmed and was associated with rapid, complete, and sustained remissions in established s.c. human lung and colon xenografts.
  • These studies show that RALBP1 is a transporter that serves as a key effector function in cancer cell survival and is a valid target for cancer therapy, and confirm that inhibitory modulation of RALBP1 transport activity at the cell surface is sufficient for antitumor effects.
  • [MeSH-major] ATP-Binding Cassette Transporters / antagonists & inhibitors. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Colonic Neoplasms / drug therapy. Colonic Neoplasms / metabolism. GTPase-Activating Proteins / antagonists & inhibitors. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Animals. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cisplatin / administration & dosage. DNA, Antisense / genetics. Humans. Immunoglobulin G / immunology. Immunoglobulin G / pharmacology. Mice. Mice, Nude. Transfection. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483352.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 104661; United States / NCI NIH HHS / CA / CA 77495; United States / NIEHS NIH HHS / ES / ES 012171
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters; 0 / DNA, Antisense; 0 / GTPase-Activating Proteins; 0 / Immunoglobulin G; 0 / RALBP1 protein, human; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


46. Cao S, Durrani FA, Rustum YM: Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res; 2004 Apr 1;10(7):2561-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
  • PURPOSE: Studies were carried out in athymic nude mice bearing human squamous cell carcinoma of the head and neck (FaDu and A253) and colon carcinoma (HCT-8 and HT-29) xenografts to evaluate the potential role of selenium-containing compounds as selective modulators of the toxicity and antitumor activity of selected anticancer drugs with particular emphasis on irinotecan, a topoisomerase I poison.
  • EXPERIMENTAL DESIGN: Antitumor activity and toxicity were evaluated using nontoxic doses (0.2 mg/mouse/day) and schedule (14-28 days) of the selenium-containing compounds, 5-methylselenocysteine and seleno-L-methionine, administered orally to nude mice daily for 7 days before i.v. administration of anticancer drugs, with continued selenium treatment for 7-21 days, depending on anticancer drugs under evaluation.
  • Several doses of anticancer drugs were used, including the maximum tolerated dose (MTD) and toxic doses.
  • Administration of these higher doses was possible due to selective protection of normal tissues by selenium.
  • Thus, the use of selenium as selective modulator of the therapeutic efficacy of anticancer drugs is new and novel.
  • CONCLUSIONS: We demonstrated that selenium is a highly effective modulator of the therapeutic efficacy and selectivity of anticancer drugs in nude mice bearing human tumor xenografts of colon carcinoma and squamous cell carcinoma of the head and neck.
  • [MeSH-major] Camptothecin / analogs & derivatives. Cysteine / analogs & derivatives. Neoplasms / drug therapy. Selenium / therapeutic use
  • [MeSH-minor] Administration, Oral. Animals. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / metabolism. Cell Line, Tumor. Colonic Neoplasms / metabolism. Dose-Response Relationship, Drug. Drug Synergism. Female. Humans. Maximum Tolerated Dose. Mice. Mice, Nude. Neoplasm Transplantation. Organoselenium Compounds / pharmacology. Radiation-Sensitizing Agents / pharmacology. Selenocysteine / analogs & derivatives. Selenomethionine / pharmacology. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SELENIUM METHIONINE .
  • Hazardous Substances Data Bank. SELENO-(DL)-CYSTEINE .
  • Hazardous Substances Data Bank. CYSTEINE .
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15073137.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16056; United States / NCI NIH HHS / CA / R01 CA76951
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoselenium Compounds; 0 / Radiation-Sensitizing Agents; 0CH9049VIS / Selenocysteine; 7673326042 / irinotecan; 964MRK2PEL / Selenomethionine; H6241UJ22B / Selenium; K848JZ4886 / Cysteine; TWK220499Z / selenomethylselenocysteine; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


47. Phan LK, Hoff PM: Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Dis Colon Rectum; 2007 Mar;50(3):395-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case.
  • Because of the high cure rate of localized anal cancers from combined modality treatment, there is little that is known for the treatment of patients who progress to have metastatic disease.
  • Treatments currently used are based on activity demonstrated in other cancers with similar histology.
  • Cetuximab, a molecular-targeted therapy, is an antibody directed against epidermal growth factor receptor that has demonstrated anticancer activity in several cancers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Carcinoma, Squamous Cell / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cetuximab. Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252287.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 7673326042 / irinotecan; PQX0D8J21J / Cetuximab; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


48. Yamatodani T, Ekblad L, Kjellén E, Johnsson A, Mineta H, Wennerberg J: Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. J Cancer Res Clin Oncol; 2009 Mar;135(3):395-402
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines.
  • OBJECTIVE: The aim of this study was to investigate the effect of epidermal growth factor receptor (EGFR) blockade on cell survival and on downstream signalling pathways using the monoclonal antibody cetuximab.
  • METHODS: We used three colon cancer cell lines, of which one was EGFR-negative, and two head and neck squamous cell carcinoma (HNSCC) lines.
  • The effect of cetuximab, irradiation or the combination of both on cell growth was estimated by SRB assay.
  • Western blotting was used to determine the phosphorylation of intracellular signalling proteins and cell cycle phase distribution was measured by flow cytometry.
  • RESULTS: The addition of cetuximab had only limited effects on cell growth, with a maximum inhibition of approximately 30%, but was correlated with the amount of protein expression and gene copy number of EGFR.
  • When combined with irradiation, the effect of cetuximab was only additive and not dependent on the inherent radio-sensitivity of the cell lines.
  • Persistent phosphorylation of Akt and/or p44/42 MAPK was detected by western blot in all of the cell lines, whereas there was no phosphorylation of Jak2 or STAT3.
  • Rather, the results suggest that it might be necessary to determine the activation status of several intracellular signalling proteins to better predict the sensitivity to cetuximab treatment.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Colonic Neoplasms / drug therapy. Head and Neck Neoplasms / drug therapy. Receptor, Epidermal Growth Factor / physiology
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / genetics. Cell Cycle / drug effects. Cell Division / drug effects. Cell Line, Tumor. Cetuximab. Cyclin D1 / genetics. Fluorescent Dyes. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Mutation. Rhodamines. Signal Transduction / drug effects. Signal Transduction / physiology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Oncol. 2006;45(3):300-5 [16644573.001]
  • [Cites] J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12 [2359136.001]
  • [Cites] J Biol Chem. 1999 Jun 11;274(24):17209-18 [10358079.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):243-7 [8195014.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):91-8 [8083133.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1935-40 [10213503.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Mar;51(3):221-6 [12655440.001]
  • [Cites] Trends Mol Med. 2007 Jan;13(1):4-11 [17118707.001]
  • [Cites] Nat Med. 2002 Oct;8(10 ):1145-52 [12244301.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5578-87 [16009949.001]
  • [Cites] J Biol Chem. 1996 Aug 23;271(34):20608-16 [8702807.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3992-5 [16618717.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2948-56 [12782602.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23 (9):1803-10 [15677699.001]
  • [Cites] Crit Rev Oral Biol Med. 2004 Sep 01;15(5):298-307 [15470267.001]
  • [Cites] Anticancer Drugs. 1995 Feb;6(1):115-23 [7538827.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2316-26 [12796401.001]
  • [Cites] Br J Cancer. 1991 Aug;64(2):251-4 [1892752.001]
  • [Cites] J Clin Invest. 2002 May;109(9):1139-42 [11994401.001]
  • [Cites] Exp Cell Res. 2003 Mar 10;284(1):31-53 [12648464.001]
  • [Cites] Cell. 1997 Oct 17;91(2):231-41 [9346240.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805 [15701870.001]
  • [Cites] Pharmacol Ther. 2004 Apr;102(1):37-46 [15056497.001]
  • [Cites] J Natl Cancer Inst. 1989 Jul 5;81(13):1020-4 [2786570.001]
  • [Cites] Biochem Pharmacol. 2005 Nov 25;70(11):1568-78 [16226226.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2489-95 [10851047.001]
  • [Cites] Oncology. 2002;63(1):92-8 [12187077.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3250-8 [12374696.001]
  • [Cites] Oncologist. 2002;7 Suppl 4:2-8 [12202782.001]
  • [Cites] Methods Mol Med. 2004;88:247-55 [14634236.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jun 22;284(4):1031-8 [11409898.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):279-86 [15863375.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2171-7 [17538161.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):8-13 [9892175.001]
  • (PMID = 18813952.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Fluorescent Dyes; 0 / Rhodamines; 136601-57-5 / Cyclin D1; 2609-88-3 / lissamine rhodamine B; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


49. Leu YS, Hsiao HT, Chang YC, Yang CC, Lee JC, Chen YJ, Chang YF: Ileocolic free flap reconstruction, concomitant chemotherapy and radiotherapy and assessment of speech and swallowing function during management of advanced cancer of the larynx and hypopharynx: preliminary report. Acta Otolaryngol; 2005 Jun;125(6):642-6
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ileocolic free flap reconstruction, concomitant chemotherapy and radiotherapy and assessment of speech and swallowing function during management of advanced cancer of the larynx and hypopharynx: preliminary report.
  • CONCLUSION: The new technique of ileocolic free flap reconstruction provides a better quality of life in terms of swallowing and speech for patients who have undergone laryngopharyngectomy with concomitant chemotherapy and radiotherapy (CCRT).
  • [MeSH-major] Colon / transplantation. Deglutition / physiology. Hypopharyngeal Neoplasms / surgery. Ileocecal Valve / transplantation. Laryngeal Neoplasms / surgery. Neoadjuvant Therapy. Reconstructive Surgical Procedures. Speech / physiology. Surgical Flaps
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Cause of Death. Follow-Up Studies. Humans. Laryngectomy / rehabilitation. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Pharyngectomy / rehabilitation. Quality of Life. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16076714.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


50. Kolh P, Honore P, Degauque C, Gielen J, Gerard P, Jacquet N: Early stage results after oesophageal resection for malignancy - colon interposition vs. gastric pull-up. Eur J Cardiothorac Surg; 2000 Sep;18(3):293-300
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early stage results after oesophageal resection for malignancy - colon interposition vs. gastric pull-up.
  • OBJECTIVE: The aims of our study were to determine if using the colon as a digestive transplant after oesophagectomy for cancer was associated with increased postoperative complications, and to assess the impact of preoperative radiochemotherapy on postoperative hospital outcome.
  • Indications were squamous cell carcinoma in 69 patients and adenocarcinoma in 61.
  • There were 84 subtotal oesophagectomies, with anastomosis in the neck in 44 patients and at the thoracic inlet in 40, and 46 distal oesophageal resections.
  • Digestive continuity was restored with the stomach in 92 patients (age: 63.4+/-10.2 years) and the colon in 38 (age: 52.3+/-12.8 years).
  • With the exception of age (P<0.0001), there was no significant preoperative difference between gastric and colonic groups.
  • One patient (2.5%) died in the colonic graft group and ten (11%) in the gastric pull-up group (P=0.17).
  • Postoperative complications occurred in 40 patients (31%), respectively, in ten (26%) and 30 (33%) patients after colonic and gastric transplants (P=0.48), and were pulmonary insufficiency or infection in 29 patients, anastomotic fistula in six, myocardial infarction in five, recurrent nerve palsy in four, renal insufficiency in three, and cerebrovascular accident in one.
  • The incidence of postoperative pulmonary complications was 70% (21/30 patients) in the subgroup who received preoperative radiochemotherapy, as compared to 11% (5/44 patients) in the subgroup of comparable staging, but without preoperative treatment (P<0.001).
  • CONCLUSIONS: Colonic grafts are not associated with increased postoperative mortality or complications.
  • Our results suggest that preoperative neoadjuvant treatment significantly increases postoperative pulmonary complications.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Colon / transplantation. Esophageal Neoplasms / surgery. Esophagus / surgery. Stomach / surgery
  • [MeSH-minor] Anastomosis, Surgical / methods. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophagectomy. Female. Hospital Mortality. Humans. Male. Middle Aged. Palliative Care. Reoperation. Retrospective Studies. Stomach Neoplasms / drug therapy. Stomach Neoplasms / mortality. Stomach Neoplasms / radiotherapy. Stomach Neoplasms / surgery. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10973538.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


51. Lièvre A, Blons H, Houllier AM, Laccourreye O, Brasnu D, Beaune P, Laurent-Puig P: Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma. Br J Cancer; 2006 Mar 13;94(5):692-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma.
  • Mitochondrial DNA mutations have been reported in several types of tumours, including head and neck squamous cell carcinoma (HNSCC).
  • The noncoding region of the Displacement-Loop (D-Loop) has emerged as a mutational hotspot and we recently found that they were associated with prognosis and response to 5 fluorouracil (5FU) in colon cancers.
  • In order to evaluate the frequence of D-Loop mutations in a large series of HNSCC and establish correlations with clinicopathologic parameters, we sequenced the D-Loop of 109 HNSCC before a treatment by neoadjuvant 5FU-cisplatin-based chemotherapy and surgery.
  • Then, we correlated these mutations with prognosis and response to chemotherapy.
  • The prevalence of D310 mutations increased significantly with the number of cytosines in the matched normal tissue sequence (P=0.02).
  • Hypopharyngeal cancer was significantly more frequent (P=0.03) and tobacco consumption more important (P=0.01) in the group of patients with D-Loop mutation.
  • The presence of D-Loop mutation was not associated with prognosis or with response to neoadjuvant chemotherapy.
  • These results suggest that D-Loop mutations should be considered as a cancer biomarker that may be useful for the early detection of HNSCC in individuals at risk of this cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / genetics. DNA, Mitochondrial / genetics. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / genetics
  • [MeSH-minor] Cisplatin / administration & dosage. DNA Mutational Analysis. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Predictive Value of Tests. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutat Res. 1999 Jul 30;434(3):177-203 [10486591.001]
  • [Cites] Curr Opin Oncol. 1999 May;11(3):200-3 [10328595.001]
  • [Cites] Head Neck. 2005 Jan;27(1):15-21 [15515158.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3517-25 [15908662.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1504-11 [11745228.001]
  • [Cites] Int J Cancer. 1999 Aug 20;84(4):410-5 [10404095.001]
  • [Cites] Oncogene. 1999 Nov 18;18(48):6641-6 [10597269.001]
  • [Cites] Science. 2000 Mar 17;287(5460):2017-9 [10720328.001]
  • [Cites] Oncogene. 2000 Apr 13;19(16):2060-6 [10803467.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4231-7 [10945635.001]
  • [Cites] Gastroenterology. 2000 Dec;119(6):1808-9 [11187439.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):319-21 [11291064.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Jan;2(1):67-71 [11413468.001]
  • [Cites] Int J Cancer. 2001 Aug 15;93(4):534-8 [11477557.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5998-6001 [11507041.001]
  • [Cites] Oncogene. 2001 Aug 23;20(37):5195-8 [11526508.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6698-702 [11559538.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7015-9 [11585726.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7623-6 [11606403.001]
  • [Cites] Int J Cancer. 2001 Nov 1;94(3):429-31 [11745425.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):481-7 [11839667.001]
  • [Cites] Oncogene. 2002 May 23;21(23):3780-3 [12032845.001]
  • [Cites] Gastroenterology. 2002 Jun;122(7):2049-63 [12055609.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2260-5 [12114429.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jun;37(2):186-94 [12696067.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2594-9 [15102660.001]
  • [Cites] Diagn Mol Pathol. 2004 Mar;13(1):26-32 [15163006.001]
  • [Cites] Eur J Cancer Prev. 2004 Jun;13(3):165-72 [15167214.001]
  • [Cites] Science. 2004 Jul 30;305(5684):626-9 [15286356.001]
  • [Cites] Chem Biol Interact. 1987;63(2):157-69 [3664791.001]
  • [Cites] Mutat Res. 1989 Sep;214(1):47-61 [2671701.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1152-5 [8118797.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1156-8 [8118798.001]
  • [Cites] Anticancer Res. 1994 Jul-Aug;14(4A):1489-92 [7979175.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):147-53 [8000993.001]
  • [Cites] Cancer Causes Control. 1996 Mar;7(2):240-52 [8740737.001]
  • [Cites] Cancer Res. 1996 Dec 15;56(24):5692-7 [8971177.001]
  • [Cites] Blood. 1997 Mar 15;89(6):1854-61 [9058704.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 18;235(2):286-90 [9199183.001]
  • [Cites] Nat Genet. 1998 Nov;20(3):291-3 [9806551.001]
  • [Cites] FEBS Lett. 1998 Dec 18;441(2):292-6 [9883902.001]
  • [Cites] Cell Death Differ. 1998 Aug;5(8):694-701 [10200525.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • (PMID = 16495928.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2361200
  •  go-up   go-down


52. Lane ME, Yu B, Rice A, Lipson KE, Liang C, Sun L, Tang C, McMahon G, Pestell RG, Wadler S: A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res; 2001 Aug 15;61(16):6170-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells.
  • Recent studies have indicated that the development of cyclin-dependent kinase (cdk)2 inhibitors that deregulate E2F are a plausible pharmacological strategy for novel antineoplastic agents.
  • This inhibition results in a time-dependent decrease (4-64%) in the phosphorylation of the retinoblastoma protein pRb, an increase in caspase-3 activation (5-84%), and alterations in cell cycle resulting in either a G(0)-G(1) or a G(2)-M block.
  • We also report here cell line differences in the cdk-dependent phosphorylation of pRb.
  • [MeSH-major] Apoptosis / drug effects. CDC2-CDC28 Kinases. Colonic Neoplasms / pathology. Cyclin-Dependent Kinases / antagonists & inhibitors. Enzyme Inhibitors / pharmacology. Imidazoles / pharmacology. Indoles / pharmacology. Protein-Serine-Threonine Kinases / antagonists & inhibitors
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Division / drug effects. Cyclin-Dependent Kinase 2. Growth Inhibitors / pharmacology. Humans. Molecular Conformation. Phosphorylation / drug effects. Retinoblastoma Protein / metabolism. Substrate Specificity. Tumor Cells, Cultured


53. de Parades V, Bauer P, Benbunan JL, Bouillet T, Cottu PH, Cuenod CA, Durdux C, Fléjou JF, Atienza P: [Initial pretherapeutic assessment of anal epidermoid carcinoma]. Gastroenterol Clin Biol; 2007 Feb;31(2):157-65
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Initial pretherapeutic assessment of anal epidermoid carcinoma].
  • Anal epidermoid carcinoma is a rare malignant tumor, comprising less than 5% of all carcinomas of the colon, rectum, and anus.
  • The primary therapy now includes radiotherapy, often in combination with chemotherapy.
  • Therapeutic indications are based on locoregional staging, the presence of visceral metastases and an evaluation of the medical history.
  • In addition, magnetic resonance imaging, positron emission tomography scanning and inguinal sentinel lymph node procedure should play a role in a more selective approach in patients with anal carcinoma.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17347624.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 96
  •  go-up   go-down


54. Kim JH, Sarani B, Orkin BA, Young HA, White J, Tannebaum I, Stein S, Bennett B: HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum; 2001 Oct;44(10):1496-502
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients.
  • PURPOSE: Anal carcinoma is being found in HIV-positive patients with increasing frequency.
  • Most patients are treated with combined chemotherapy and radiation.
  • It was our impression that HIV-positive patients do not fare as well as HIV-negative patients in terms of both response to and tolerance of therapy.
  • METHODS: To test this hypothesis, we reviewed our experience with anal carcinoma and compared HIV-positive to HIV-negative patients by age, gender, sexual orientation, stage at diagnosis, treatment rendered, response to treatment, tolerance, and survival.
  • Seventy-three patients had invasive squamous-cell carcinoma (including cloacogenic carcinoma), and this cohort was analyzed.
  • Acute treatment major toxicity differed significantly (HIV positive 80 percent vs. HIV negative 30 percent; P < 0.005).
  • Only 62 percent of HIV-positive patients were rendered disease free after initial therapy vs. 85 percent of HIV-negative patients (P = 0.11).
  • Median time to cancer-related death was 1.4 vs. 5.3 years (P < 0.05).
  • A survival model did not show age, gender, stage, or treatment to be independent predictors.
  • CONCLUSION: We found that HIV-positive patients with anal carcinoma seem to be a different population from HIV-negative patients by age, gender, and sexual orientation.
  • They have a poorer tolerance for combined therapy and a shorter time to cancer-related death.
  • These results suggest that the treatment of HIV-positive patients with anal carcinoma needs to be reassessed.
  • [MeSH-major] Anus Neoplasms / complications. Anus Neoplasms / therapy. HIV Infections / complications
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy Dosage. Treatment Outcome

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11598480.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


55. Provencher S, Oehler C, Lavertu S, Jolicoeur M, Fortin B, Donath D: Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma. Radiat Oncol; 2010;5:41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma.
  • PURPOSE: To evaluate quality of life (QOL) and outcome of patients with anal carcinoma treated with short split-course chemoradiation (CRT).
  • External beam radiotherapy (52 Gy/26 fractions) with elective groin irradiation (24 Gy) was applied in 2 series divided by a median gap of 12 days.
  • Chemotherapy including fluorouracil and Mitomycin-C was delivered in two sequences.
  • CONCLUSIONS: Short split-course CRT for anal carcinoma seems to be associated with good local control, survival and long-term global QOL.
  • Implementation of modern techniques such as intensity-modulated radiation therapy (IMRT) might be considered to reduce toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Quality of Life. Radiotherapy Dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1274-83 [12873671.001]
  • [Cites] Brachytherapy. 2007 Jul-Sep;6(3):218-26 [17681244.001]
  • [Cites] Br J Surg. 1985 Apr;72(4):282-5 [3986477.001]
  • [Cites] Cancer. 1991 May 15;67(10):2462-6 [2015547.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Dis Colon Rectum. 1998 Apr;41(4):441-50 [9559628.001]
  • [Cites] Br J Cancer. 1999 Jul;80(10):1588-94 [10408404.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2004 Dec;16(8):530-5 [15630846.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4581-6 [17925552.001]
  • [Cites] Radiother Oncol. 2007 Aug;84(2):107-13 [17707936.001]
  • [Cites] Radiother Oncol. 1999 Sep;52(3):239-43 [10580870.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):77-84 [11443612.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):45-51 [12504657.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):669-78 [12573754.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(2):189-93 [17189954.001]
  • [Cites] Eur J Cancer. 2007 Jul;43(10):1564-73 [17521904.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • (PMID = 20492729.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2883545
  •  go-up   go-down


56. Kim IA, Kim IH, Kim HJ, Chie EK, Kim JS: HDAC inhibitor-mediated radiosensitization in human carcinoma cells: a general phenomenon? J Radiat Res; 2010;51(3):257-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HDAC inhibitor-mediated radiosensitization in human carcinoma cells: a general phenomenon?
  • Histone deacetylase inhibitors (HDIs) have attracted considerable attention for anticancer therapy strategy, including radiosensitization.
  • Regarding a potential application of HDI as a radiosensitizer in the treatment of solid tumors, an important question is whether treatment efficacy would be influenced by intrinsic differences between cancer cells, such as different histologic origin and status of ATM or p53.
  • First we have observed the in vitro radiosensitization by Trichostatin A (TSA) on the broad spectrum of human tumor cell lines having different histologic origin such as HCT116 adenocarcinoma of colon, A549 adenocarcinoma of lung, HN-3 squamous cell carcinoma of head/neck, and HeLa squamous carcinoma of uterine cervix, using clonogenic assay.
  • Next, we have systematically assessed the radiosensitization on the cell lines having different ATM or p53 status.
  • We found that pretreatment of HDI consistently resulted in radiosensitization of all cell lines tested, though the sensitizer enhancement ratio of individual cell lines was variable.
  • The data presented here indicate that HDI enhances the radiation induced cell killing in the various cancer cells having intrinsic differences and may serve as a general strategy for enhancing tumor cell radiosensitivity.
  • [MeSH-major] Carcinoma / drug therapy. Carcinoma / radiotherapy. Enzyme Inhibitors / pharmacology. Histone Deacetylase Inhibitors / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Dose-Response Relationship, Radiation. Genes, p53. HeLa Cells. Humans. Hydroxamic Acids / pharmacology. Male. Radiation Tolerance. Radiation-Sensitizing Agents / pharmacology. Time Factors

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505264.001).
  • [ISSN] 1349-9157
  • [Journal-full-title] Journal of radiation research
  • [ISO-abbreviation] J. Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Radiation-Sensitizing Agents; 3X2S926L3Z / trichostatin A
  •  go-up   go-down


57. Birle DC, Hedley DW: Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. Cancer Res; 2007 Feb 15;67(4):1735-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors.
  • Experimental data suggest therapeutic advantage from selective disruption of the hypoxia response.
  • We recently found that the proteasome inhibitor bortezomib decreases tumor carbonic anhydrase IX (CAIX) expression in colon cancer patients and herein report a companion laboratory study to test if this effect was the result of hypoxia-inducible factor (HIF) inhibition.
  • Human cervical (SiHa and Me180) and colon (RKO) carcinoma cell lines were treated with bortezomib or the structurally unrelated proteasome inhibitor MG132 in normoxic and hypoxic conditions in vitro.
  • Treatment with either drug produced accumulation of HIF-1alpha in vitro but strongly inhibited the production of CAIX and vascular endothelial growth factor (VEGF) under hypoxia.
  • Plasma VEGF levels decreased by approximately 90% during treatment with bortezomib, indicating that this agent can potently inhibit the hypoxia response in tumors.
  • [MeSH-major] Boronic Acids / pharmacology. Carcinoma, Squamous Cell / drug therapy. Hypoxia-Inducible Factor 1, alpha Subunit / antagonists & inhibitors. Leupeptins / pharmacology. Protease Inhibitors / pharmacology. Pyrazines / pharmacology. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Antigens, Neoplasm / biosynthesis. Antineoplastic Agents / pharmacology. Bortezomib. Carbonic Anhydrases / biosynthesis. Caspase 3 / metabolism. Cell Hypoxia / physiology. Cell Line, Tumor. Cell Nucleus / metabolism. Colonic Neoplasms / drug therapy. Colonic Neoplasms / metabolism. E1A-Associated p300 Protein / metabolism. Enzyme Activation / drug effects. Female. Humans. Male. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / metabolism. Protein Binding. Vascular Endothelial Growth Factor A / biosynthesis. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17308115.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Leupeptins; 0 / Protease Inhibitors; 0 / Pyrazines; 0 / Vascular Endothelial Growth Factor A; 133407-82-6 / benzyloxycarbonylleucyl-leucyl-leucine aldehyde; 69G8BD63PP / Bortezomib; EC 2.3.1.48 / E1A-Associated p300 Protein; EC 2.3.1.48 / EP300 protein, human; EC 3.4.22.- / Caspase 3; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


58. Siemann DW, Norris CM, Ryan A, Shi W: Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474). Anticancer Res; 2009 Jun;29(6):1987-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).
  • MATERIALS AND METHODS: Human colon carcinoma (HT29) and murine squamous carcinoma (SCCVII) clonal cell lines expressing varying levels of VEGF were established and their response to vandetanib was assessed in tissue culture and as solid tumors.
  • RESULTS: Vandetanib treatment had no effect on tumor cell clonogenic cell survival in vitro but doses >or=10 nM significantly reduced endothelial cell migration.
  • In vivo, tumors derived from cell clones expressing high levels of VEGF displayed significantly enhanced angiogenesis and more aggressive growth.
  • An intradermal angiogenesis assay was used to demonstrate that a 4-day treatment with vandetanib (50 mg/kg/day) was able to significantly inhibit blood vessel growth induced by both parental and high VEGF-expressing tumor cell clones.
  • In the HT29 tumor model, treatment response to vandetanib (50 mg/kg/day, Monday-Friday for 2 weeks) was greatest in xenografts derived from the highest VEGF-expressing cell clones.
  • The present findings indicate that vandetanib therapy effectively counteracted the aggressive feature of tumor growth resulting from VEGF over-expressing tumor cells and suggest that such tumors may be particularly well suited for anti-VEGF interventions.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):573-83 [12154350.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4645-55 [12183421.001]
  • [Cites] Expert Opin Investig Drugs. 2002 Dec;11(12):1715-36 [12457433.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 [12516034.001]
  • [Cites] J Clin Pathol. 2004 May;57(5):504-12 [15113858.001]
  • [Cites] Mol Cancer Ther. 2004 Sep;3(9):1041-8 [15367698.001]
  • [Cites] Cancer Res. 1976 Sep;36(9 PT 2):3435-40 [975113.001]
  • [Cites] J Cell Physiol. 1992 Dec;153(3):557-62 [1447317.001]
  • [Cites] J Immunol. 1994 Apr 15;152(8):4149-56 [7511670.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):768-72 [7531342.001]
  • [Cites] J Biol Chem. 1995 Apr 28;270(17):9709-16 [7730348.001]
  • [Cites] Ann Oncol. 1995 Oct;6(8):817-25 [8589021.001]
  • [Cites] J Biol Chem. 1996 Jan 12;271(2):603-6 [8557658.001]
  • [Cites] Cancer Sci. 2004 Dec;95(12):984-9 [15596048.001]
  • [Cites] Angiogenesis. 2004;7(4):347-54 [15886878.001]
  • [Cites] Br J Cancer. 2005 Jun;92 Suppl 1:S6-13 [15928657.001]
  • [Cites] Oncology. 2005;69 Suppl 3:4-10 [16301830.001]
  • [Cites] Science. 2006 May 26;312(5777):1171-5 [16728631.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):836-41 [16751064.001]
  • [Cites] Oncol Res. 2006;16(1):15-26 [16783964.001]
  • [Cites] In Vivo. 2006 Nov-Dec;20(6B):815-21 [17203773.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jun;62(3):179-213 [17324579.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1349-57 [17537667.001]
  • [Cites] Curr Med Chem. 2007;14(23):2495-516 [17979703.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7487-95 [18094433.001]
  • [Cites] Ann Surg Oncol. 2008 Mar;15(3):738-44 [18043973.001]
  • [Cites] J Transl Med. 2008;6:1 [18171482.001]
  • [Cites] World J Gastroenterol. 2008 Mar 28;14(12):1931-5 [18350635.001]
  • [Cites] Radiat Res. 1991 May;126(2):237-43 [1708892.001]
  • [Cites] J Investig Dermatol Symp Proc. 2000 Dec;5(1):24-33 [11147671.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1207-25 [11181687.001]
  • [Cites] Apoptosis. 2000 Oct;5(4):323-8 [11227213.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1104-17 [11451738.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1702-6 [11912143.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):119-26 [12085267.001]
  • [Cites] Curr Opin Pharmacol. 2002 Aug;2(4):403-14 [12127873.001]
  • (PMID = 19528456.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA089655-07; United States / NCI NIH HHS / CA / R01 CA089655; United States / NCI NIH HHS / CA / CA089655; United States / NCI NIH HHS / CA / R01 CA089655-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 0 / Piperidines; 0 / Quinazolines; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / vascular endothelial growth factor A, mouse
  • [Other-IDs] NLM/ NIHMS159150; NLM/ PMC2786495
  •  go-up   go-down


59. Whelan LC, Ryan MF: Effects of the polyacetylene capillin on human tumour cell lines. Anticancer Res; 2004 Jul-Aug;24(4):2281-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of the polyacetylene capillin on human tumour cell lines.
  • We investigated the effects of capillin, a constituent of Artemisia monosperma, on four human tumour cell lines: colon carcinoma H729, pancreatic carcinoma MIA PaCa-2, epidermoid carcinoma of the larynx HEp-2 and lung carcinoma A549.
  • Changes in cell proliferation, membrane permeability, macromolecular synthesis, glutathione (GSH), cell cycle and programmed cell death were evaluated.
  • Capillin (1microM-10microM) inhibited cell proliferation and decreased macromolecular synthesis simultaneously, in a dose- and time-dependent manner.
  • Co-incubation with L-buthionine sulfoximine (L-BSO) augmented the efficacy of capillin.
  • Capillin modulated GSH levels, accumulated cells in the S+G2/M-phase of the cell cycle and induced cell death and DNA fragmentation, as indicated by flow cytometry, fluorescence microscopy and DNA fragmentation assay.
  • These findings suggest that capillin has cytotoxic activity and can induce apoptosis in human tumour cell lines.
  • [MeSH-minor] Apoptosis / drug effects. Buthionine Sulfoximine / pharmacology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Cycle / drug effects. Cell Division / drug effects. Cell Line, Tumor. Colonic Neoplasms / drug therapy. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. DNA, Neoplasm / antagonists & inhibitors. DNA, Neoplasm / biosynthesis. Diynes. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Glutathione / metabolism. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / metabolism. Laryngeal Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Neoplasm Proteins / antagonists & inhibitors. Neoplasm Proteins / biosynthesis. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Plant Extracts / pharmacology. RNA, Neoplasm / antagonists & inhibitors. RNA, Neoplasm / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15330173.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Alkynes; 0 / Antineoplastic Agents, Phytogenic; 0 / DNA, Neoplasm; 0 / Diynes; 0 / Neoplasm Proteins; 0 / Plant Extracts; 0 / RNA, Neoplasm; 495-74-9 / capillin; 5072-26-4 / Buthionine Sulfoximine; GAN16C9B8O / Glutathione
  •  go-up   go-down


60. Backus HH, Pinedo HM, Wouters D, Padrón JM, Molders N, van Der Wilt CL, van Groeningen CJ, Jansen G, Peters GJ: Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. Int J Cancer; 2000 Sep 15;87(6):771-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates.
  • Cancer cell lines in standard cell culture medium or in animal models are surrounded by an environment with relatively high folate (HF) levels, compared with folate levels in human plasma.
  • In the present study we adapted 4 colon cancer (C26-A, C26-10, C26-G and WiDr) and 3 squamous cell carcinoma of the head and neck (HNSCC) cell lines (11B, 14C and 22B) to culture medium with low folate (LF) levels (2.5, 1.0 and 0.5 nM, respectively) and investigated whether folate depletion had an effect on sensitivity to antifolates and which mechanisms were involved.
  • All LF cell lines showed a higher sensitivity to 5-fluorouracil (5-FU) alone or in combination with leucovorin (LV) (2-5-fold), to the thymidylate synthase (TS) inhibitors, AG337 (2-7-fold), ZD1694 (3-49-fold), ZD9331 (3-40-fold), LY231514 (2-21-fold) or GW1843U89 (4-29-fold) or to the dihydrofolate reductase (DHFR) inhibitor PT523 (2-50-fold) compared with their HF variants cultured in standard medium containing up to 8 microM folic acid.
  • LV could only increase sensitivity to 5-FU in HNSCC cell lines 14C and 14C/F.
  • The differences in sensitivity could partially be explained by a 2-7-fold increased transport activity of the reduced folate carrier (RFC) in LF cell lines, whereas no significant change in folylpolyglutamate synthetase (FPGS) activity was observed.
  • Furthermore, the protein expression and catalytic activity of the target enzyme TS were up to 7-fold higher in HF colon cancer cells compared with the LF variants (p < 0.05).
  • The folate levels in LF medium used in this study are more representative for folate levels in human plasma and therefore these data could be more predictive for the activity of 5-FU and antifolates in a clinical setting than results obtained from cell lines cultured in HF medium or in animal models.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Fluorouracil / pharmacology. Folic Acid / metabolism. Folic Acid Antagonists / pharmacology. Membrane Proteins. Membrane Transport Proteins. Neoplasms / drug therapy. Neoplasms / metabolism. Thymidylate Synthase / metabolism
  • [MeSH-minor] Animals. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / metabolism. Carrier Proteins / metabolism. Colonic Neoplasms / drug therapy. Colonic Neoplasms / metabolism. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / metabolism. Humans. Leucovorin / therapeutic use. Lung Neoplasms. Mice. Multienzyme Complexes / antagonists & inhibitors. Peptide Synthases / metabolism. Reduced Folate Carrier Protein. Tetrahydrofolate Dehydrogenase. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10956384.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Carrier Proteins; 0 / Folic Acid Antagonists; 0 / Membrane Proteins; 0 / Membrane Transport Proteins; 0 / Multienzyme Complexes; 0 / Reduced Folate Carrier Protein; 0 / SLC19A1 protein, human; 0 / SLC19A2 protein, human; 0 / Slc19a1 protein, mouse; 0 / Slc19a2 protein, mouse; 0 / thymidylate synthase-dihydrofolate reductase; 935E97BOY8 / Folic Acid; EC 1.5.1.3 / Tetrahydrofolate Dehydrogenase; EC 2.1.1.45 / Thymidylate Synthase; EC 6.3.2.- / Peptide Synthases; EC 6.3.2.17 / folylpolyglutamate synthetase; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


61. Devon KM, Brown CJ, Burnstein M, McLeod RS: Cancer of the anus complicating perianal Crohn's disease. Dis Colon Rectum; 2009 Feb;52(2):211-6
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This study was designed to review the clinical and pathologic findings, treatment, and outcomes of patients who have a cancer that complicates perianal Crohn's disease.
  • METHODS: Charts of patients who had documented perianal Crohn's disease and a pathologic diagnosis of anal carcinoma were reviewed.
  • There were 11 adenocarcinomas (8 mucinous or colloid subtypes) and 3 squamous-cell carcinomas.
  • Treatment included abdominoperineal resections plus chemotherapy in 12, and radiation and a defunctioning stoma in 1 patient.
  • In this series, patients who were diagnosed preoperatively and treated with multimodality therapy had better outcomes.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Adult. Aged. Anal Canal / pathology. Anus Diseases / complications. Anus Diseases / pathology. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / diagnosis. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19279414.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Ouban A, Nawab RA, Coppola D: Diagnostic and pathogenetic implications of colorectal carcinomas with multidirectional differentiation: a report of 4 cases. Clin Colorectal Cancer; 2002 Feb;1(4):243-8
Hazardous Substances Data Bank. Carminic acid .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two tumors were located in the right colon, one in the splenic flexure, and one in the descending colon.
  • Histologically, two tumors exhibited neuroendocrine and glandular differentiation; the third tumor was an adenocarcinoma with a sarcomatous component and the fourth tumor showed 3 lines of differentiation (glandular, squamous, and sarcomatoid).
  • The squamous cell component was AE3 positive and CAM 5.2 negative.
  • One patient was on supportive care for terminal metastatic carcinoma, and 2 patients were being treated with adjuvant chemotherapy at the time of this report.
  • Colon carcinoma with multidirectional differentiation is a rare event and may originate from stem cells within the gastrointestinal mucosa, and/or represent the convergence of multiple tumors arising at the same site.
  • This type of tumor should be considered in the differential diagnosis of a bowel biopsy with multiple histopathologic variants.
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Carcinoma, Squamous Cell / pathology. Cell Transformation, Neoplastic. Coloring Agents / analysis. Female. Humans. Immunohistochemistry. Keratins / analysis. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12450423.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 51395-97-2 / mucicarmine; 68238-35-7 / Keratins; CID8Z8N95N / Carmine
  •  go-up   go-down


63. Oehler C, Provencher S, Donath D, Bahary JP, Lütolf UM, Ciernik IF: Chemo-radiation with or without mandatory split in anal carcinoma: experiences of two institutions and review of the literature. Radiat Oncol; 2010;5:36
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemo-radiation with or without mandatory split in anal carcinoma: experiences of two institutions and review of the literature.
  • METHODS: Eighty-four patients with invasive anal cancer treated with definitive external beam radiotherapy (RT) with a mandatory split of 12 days (52 patients, Montreal, Canada) or without an intended split (32 patients, Zurich, Switzerland) were reviewed.
  • Total RT doses were 52 Gy (Montreal) or 59.4 Gy (Zurich) given concurrently with 5-FU/MMC.
  • Patients from Zurich with prolonged treatment interruption (> or = 7 d) had impaired cancer-specific survival compared with patients with only minor interruption (<7 d) (P = 0.06).
  • CONCLUSIONS: The study design did not allow demonstrating a clear difference in efficacy between the treatment regimens with or without short mandatory split.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy, Conformal
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Radiation. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Retrospective Studies. Review Literature as Topic. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1394-400 [17276620.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800 [17379452.001]
  • [Cites] Brachytherapy. 2007 Jul-Sep;6(3):218-26 [17681244.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4581-6 [17925552.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Onkologie. 2008 May;31(5):251-7 [18497514.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):376-82 [18453023.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):367-75 [18501453.001]
  • [Cites] Cancer J Sci Am. 1996 Jul-Aug;2(4):205-11 [9166533.001]
  • [Cites] Acta Oncol. 2006;45(6):728-35 [16938816.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):354-61 [16168830.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1136-42 [15752894.001]
  • [Cites] Oncology. 1998 Nov-Dec;55(6):525-32 [9778618.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):651-7 [9336145.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2329-35 [9191520.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Int J Colorectal Dis. 1992 Dec;7(4):192-6 [1293239.001]
  • [Cites] Ann Surg. 1992 Feb;215(2):150-6 [1546901.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Cancer. 1991 May 15;67(10):2462-6 [2015547.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 7;81(11):850-6 [2724350.001]
  • [Cites] Oncology. 2003;65(1):14-22 [12837978.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):77-84 [11443612.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):45-51 [12504657.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):823-31 [12788191.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):114-8 [18472363.001]
  • [Cites] Eur J Surg Oncol. 2008 Aug;34(8):890-4 [18178364.001]
  • [Cites] Radiother Oncol. 2000 Oct;57(1):91-6 [11033193.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):675-80 [11395235.001]
  • (PMID = 20465811.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2879246
  •  go-up   go-down


64. Levitsky J, Hong JJ, Jani AB, Ehrenpreis ED: Oral vitamin a therapy for a patient with a severely symptomatic postradiation anal ulceration: report of a case. Dis Colon Rectum; 2003 May;46(5):679-82
Hazardous Substances Data Bank. VITAMIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral vitamin a therapy for a patient with a severely symptomatic postradiation anal ulceration: report of a case.
  • Squamous-cell carcinoma of the anus is an uncommon but treatable gastrointestinal malignancy.
  • Radiation, in addition to chemotherapy, is widely accepted as the standard of care for treatment in most patients.
  • However, significant anal complications, such as stricture, fistula, and ulceration, may result from radiation therapy.
  • Some medical therapies have been used for radiation proctopathy, but treatments for radiation-induced anal injury other than surgical diversion are unknown.
  • We report a case of a patient with human immunodeficiency virus infection who developed a symptomatic anal ulcer after receiving high-dose radiotherapy for anal squamous-cell carcinoma.
  • Vitamin A seems to be very effective in the treatment of radiation-induced anorectal damage, with little toxicity and expense.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Fissure in Ano / drug therapy. Radiation Injuries / drug therapy. Vitamin A / administration & dosage
  • [MeSH-minor] Administration, Oral. Adult. Combined Modality Therapy. HIV Infections / complications. Humans. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin A.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12792447.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11103-57-4 / Vitamin A
  •  go-up   go-down


65. Martin JM, Molina I, Monteagudo C, Marti N, Lopez V, Jorda E: Buschke-Lowenstein tumor. J Dermatol Case Rep; 2008 Dec 27;2(4):60-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Verrucous carcinoma of the skin and mucosa is an uncommon type of well-differentiated squamous cell carcinoma.
  • Treatment is controversial.
  • Topical chemotherapy, radiotherapy, immunotherapy and radical surgery have been employed.
  • MAIN OBSERVATIONS: We report a rapidly progressing penile verrucous carcinoma which was treated sucessfuly with conservative surgery and CO2 laser.
  • CONCLUSION: Treatment with CO2 laser in combination with conservative surgery may be a therapeutic option in Buschke-Lowenstein tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Dermatopathol. 2006 Dec;28(6):526-36 [17122499.001]
  • [Cites] Langenbecks Arch Surg. 2008 Jan;393(1):111-4 [17609975.001]
  • [Cites] Adv Anat Pathol. 2008 Sep;15(5):263-78 [18724100.001]
  • [Cites] Dermatology. 2009;218(1):56-9 [18936533.001]
  • [Cites] Dis Colon Rectum. 1989 Jun;32(6):481-7 [2791784.001]
  • [Cites] Histopathology. 1988 Mar;12(3):319-23 [2835300.001]
  • [Cites] Br J Obstet Gynaecol. 1988 Apr;95(4):414-8 [2838068.001]
  • [Cites] Int J Cancer. 1982 Feb 15;29(2):143-6 [6277807.001]
  • [Cites] Langenbecks Arch Chir. 1995;380(2):115-8 [7760649.001]
  • [Cites] Dis Colon Rectum. 1994 Sep;37(9):950-7 [8076499.001]
  • [Cites] Eur J Surg. 1995 Sep;161(9):691-4 [8541430.001]
  • [Cites] Arch Dermatol. 2000 Jun;136(6):707-10 [10871930.001]
  • [Cites] Ann Urol (Paris). 2002 Jul;36(4):286-9 [12162196.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1201-4 [12168925.001]
  • [Cites] J Am Acad Dermatol. 1995 Jan;32(1):1-21; quiz 22-4 [7822496.001]
  • [Cites] Ann Plast Surg. 1997 Jun;38(6):653-7 [9188985.001]
  • [Cites] Dermatology. 2003;207(1):119-22 [12835572.001]
  • [Cites] Asian J Surg. 2005 Jul;28(3):238-40 [16024325.001]
  • [Cites] Ann Urol (Paris). 2006 Jun;40(3):175-8 [16869538.001]
  • (PMID = 21886716.001).
  • [ISSN] 1898-7249
  • [Journal-full-title] Journal of dermatological case reports
  • [ISO-abbreviation] J Dermatol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC3157782
  • [Keywords] NOTNLM ; condylomata acuminata / lasers / penile neoplasms / squamous cell carcinoma / verrucous carcinoma
  •  go-up   go-down


66. Trombetta LJ, Place RJ: Giant condyloma acuminatum of the anorectum: trends in epidemiology and management: report of a case and review of the literature. Dis Colon Rectum; 2001 Dec;44(12):1878-86
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment included wide local excision and partial closure with rotation flaps.
  • Pathology revealed a giant condyloma acuminatum with foci of well-differentiated squamous-cell carcinoma.
  • Foci of invasive carcinoma are noted in 50 percent of the reports, "carcinoma in situ" in 8 percent, and no invasion in 42 percent.
  • Historically, treatment strategies have included topical chemotherapy, wide local excision, abdominopelvic resection, and the frequent addition of adjuvant and neoadjuvant systemic chemotherapy and radiation therapy.
  • Complete excision is the preferred initial therapy when feasible.
  • Chemotherapy with 5-fluorouracil and focused radiation therapy may be used in certain cases of recurrence or extensive pelvic disease, with unpredictable response.
  • Controlled, prospective, multi-institutional studies are necessary to further define the nature and treatment of this rare disease.
  • [MeSH-minor] Adult. Anus Neoplasms / complications. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / surgery. Humans. Male. Rectal Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - Genital Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11742180.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


67. Blazy A, Hennequin C, Gornet JM, Furco A, Gérard L, Lémann M, Maylin C: Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Dis Colon Rectum; 2005 Jun;48(6):1176-81
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy.
  • BACKGROUND: Anal carcinoma, a common disease in HIV-positive patients, is usually treated with chemoradiotherapy.
  • Generally tolerance was poor before the availability of highly active antiretroviral therapies.
  • We report our experience of treating anal carcinoma in the era of new antiviral drugs.
  • PATIENTS AND METHODS: Between 1997 and 2001, nine men on highly active antiretroviral therapies with good immune status before chemoradiotherapy received concomitant chemoradiotherapy consisting of 5-fluorouracil and cisplatinum, and high-dose radiotherapy (60-70 Gy) for anal carcinoma.
  • CD4+ cell counts were <200/ml for four patients, between 200/ml and 500/ml for four, and >500/ml for one.
  • RESULTS: All patients received the planned dose of radiation (> or = 60 Gy).
  • The chemotherapy dose was reduced 25 percent in six patients.
  • Overall treatment time was 58 days.
  • No association was observed between high-grade toxicity and CD4+ cell count.
  • None of the patients developed opportunistic infections during follow-up.
  • One patient with T4N2 disease relapsed locally one year after treatment and underwent salvage abdominoperineal excision.
  • CONCLUSION: High-dose chemoradiotherapy for anal carcinomas is feasible with low toxicity in HIV-positive patients treated with highly active antiretroviral therapies.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. HIV Infections / complications
  • [MeSH-minor] Adult. Anti-Retroviral Agents / administration & dosage. Antiretroviral Therapy, Highly Active. Combined Modality Therapy. Dose-Response Relationship, Drug. Feasibility Studies. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15906137.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


68. Chow LQ, Eckhardt SG: Sunitinib: from rational design to clinical efficacy. J Clin Oncol; 2007 Mar 1;25(7):884-96
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tyrosine kinase inhibitors such as SU6668 and SU5416 (semaxanib) demonstrated poor pharmacologic properties and limited efficacy; therefore, sunitinib was rationally designed and chosen for its high bioavailability and its nanomolar-range potency against the antiangiogenic receptor tyrosine kinases (RTKs)--vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR).
  • Sunitinib inhibits other tyrosine kinases including, KIT, FLT3, colony-stimulating factor 1 (CSF-1), and RET, which are involved in a number of malignancies including small-cell lung cancer, GI stromal tumors (GISTs), breast cancer, acute myelogenous leukemia, multiple endocrine neoplasia types 2A and 2B, and familial medullary thyroid carcinoma.
  • Sunitinib demonstrated robust antitumor activity in preclinical studies resulting not only in tumor growth inhibition, but tumor regression in models of colon cancer, non-small-cell lung cancer, melanoma, renal carcinoma, and squamous cell carcinoma, which were associated with inhibition of VEGFR and PDGFR phosphorylation.
  • Clinical activity was demonstrated in neuroendocrine, colon, and breast cancers in phase II studies, whereas definitive efficacy has been demonstrated in advanced renal cell carcinoma and in imatinib-refractory GISTs, leading to US Food and Drug Administration approval of sunitinib for treatment of these two diseases.
  • Studies investigating sunitinib alone in various tumor types and in combination with chemotherapy are ongoing.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Agents / therapeutic use. Indoles / therapeutic use. Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Pyrroles / therapeutic use
  • [MeSH-minor] Animals. Carcinoma, Renal Cell / drug therapy. Clinical Trials as Topic. Drug Design. Gastrointestinal Stromal Tumors / drug therapy. Humans. Kidney Neoplasms / drug therapy. Leukemia, Myeloid, Acute / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Jul 1;25(19):2858-9; author reply 2859-61 [17602094.001]
  • (PMID = 17327610.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Indoles; 0 / Protein Kinase Inhibitors; 0 / Pyrroles; 0 / sunitinib
  • [Number-of-references] 112
  •  go-up   go-down


69. Runfola MA, Weber TK, Rodriguez-Bigas MA, Dougherty TJ, Petrelli NJ: Photodynamic therapy for residual neoplasms of the perianal skin. Dis Colon Rectum; 2000 Apr;43(4):499-502
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for residual neoplasms of the perianal skin.
  • PURPOSE: The aim of this study was to evaluate the efficacy of photodynamic therapy in the management of residual neoplasms of the perianal skin.
  • Five patients with pathologic confirmation of residual perianal neoplasms were treated with photodynamic therapy.
  • Pathology consisted of Bowen's disease in two patients, squamous-cell carcinoma in two patients, and extramammary Paget's disease in one patient.
  • Four patients received one photodynamic therapy treatment and one patient received two treatments three months apart.
  • RESULTS: Treatment was followed by immediate perianal erythema, subsequent blister formation in 36 to 48 hours, and sloughing of the treated area in 72 hours.
  • One recurrence was in a patient four years after treatment for Paget's disease, and the other was in a patient nine months after treatment for Bowen's disease.
  • Treatment-related toxicities included significant perianal pain in four patients, controlled with analgesia management.
  • CONCLUSIONS: Photodynamic therapy can successfully be used after wide local excision for residual neoplasms of the perianal skin.
  • Treatment can be rendered with acceptable morbidity.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / drug therapy. Bowen's Disease / drug therapy. Carcinoma, Squamous Cell / drug therapy. Paget Disease, Extramammary / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm, Residual. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10789745.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


70. Salnikov AV, Gladkich J, Moldenhauer G, Volm M, Mattern J, Herr I: CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer; 2010 Feb 15;126(4):950-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.
  • Despite advances in anticancer treatment, lung cancer still has poor prognosis.
  • Recently, a cancer stem cell (CSC) hypothesis has emerged describing a small subset of tumor cells with stem cell properties.
  • CSCs found in many solid tumors express CD133 antigen on the cell surface.
  • The presence of CSC is correlated with poor survival of patients with glioblastomas, colon or prostate cancers.
  • In this study, we evaluated whether CD133 expression in non-small cell lung cancer (NSCLC) has a prognostic value in patients' survival.
  • We found no correlation between CD133 positivity or the amount of CD133(+) cells with NSCLC patients' survival, expression of oncogenes c-myc, c-N-ras, c-jun, c-fos, c-erbB1, c-erbB2 or p53, angiogenic factors VEGF, VEGFR-1, FGF, FGFR-1, tissue factor and with proliferative activity or apoptosis in NSCLC tissues.
  • Because CD133 expression is linked to a resistant phenotype, detection of CD133(+) cells may be useful to predict efficacy of cytotoxic therapy but CD133 is not a strong prognostic parameter for survival of patients with NSCLC.
  • [MeSH-major] Antigens, CD / analysis. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / pathology. Glycoproteins / analysis. Lung Neoplasms / pathology. Peptides / analysis
  • [MeSH-minor] Aged. Animals. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Drug Resistance, Neoplasm. Female. Glioblastoma / mortality. Glioblastoma / pathology. Humans. Immunohistochemistry. Male. Mice. Mice, Nude. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Testicular Neoplasms / mortality. Testicular Neoplasms / pathology. Transplantation, Heterologous


71. Di Paolo C, Willuda J, Kubetzko S, Lauffer I, Tschudi D, Waibel R, Plückthun A, Stahel RA, Zangemeister-Wittke U: A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res; 2003 Jul;9(7):2837-48
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity.
  • PURPOSE: Epithelial cell adhesion molecule (Ep-CAM) is a tumor-associated antigen overexpressed in many solid tumors but shows limited expression in normal epithelial tissues.
  • To exploit this favorable expression pattern for targeted cancer therapy, an Ep-CAM-specific recombinant immunotoxin was developed and its antitumor activity investigated.
  • EXPERIMENTAL DESIGN: The immunotoxin 4D5MOCB-ETA was developed by genetically fusing a truncated form of Pseudomonas aeruginosa exotoxin A (ETA) (ETA(252-608)KDEL) to the highly stable humanized single-chain antibody fragment (scFv) 4D5MOCB.
  • Cytotoxicity of 4D5MOCB-ETA was measured in cell growth and leucine incorporation assays in vitro.
  • In vitro, 4D5MOCB-ETA potently and specifically inhibited protein synthesis and reduced the viability of Ep-CAM-positive carcinoma cells of diverse histological origins with IC(50)s ranging from 0.005 to 0.2 pM.
  • The potent antitumor activity of 4D5MOCB-ETA was demonstrated by its ability to strongly inhibit the growth and induce regression of relatively large tumor xenografts derived from lung, colon, or squamous cell carcinomas.
  • CONCLUSIONS: We describe for the first time the development of a fully recombinant Ep-CAM-specific immunotoxin and demonstrate its potent activity against solid tumors of various histological origins.
  • 4D5MOCB-ETA is currently being evaluated in a Phase I study in patients with refractory squamous cell carcinoma of the head and neck.
  • [MeSH-minor] ADP Ribose Transferases / chemistry. Animals. Antineoplastic Agents / pharmacology. Cell Adhesion Molecules. Cell Division. Cell Line, Tumor. Chromatography, Gel. Dose-Response Relationship, Drug. Exotoxins / chemistry. Female. Flow Cytometry. Genetic Vectors. Humans. Inhibitory Concentration 50. Mice. Mice, Inbred C57BL. Mice, Nude. Models, Molecular. Neoplasm Transplantation. Protein Structure, Tertiary. Time Factors. Virulence Factors / chemistry

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Cancer Res. 2004 Apr 1;10(7):2579
  • (PMID = 12855664.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bacterial Toxins; 0 / Cell Adhesion Molecules; 0 / Exotoxins; 0 / Immunoglobulin Fragments; 0 / Immunotoxins; 0 / Recombinant Proteins; 0 / Virulence Factors; 0 / immunotoxin 4D5MOCB-ETA; EC 2.4.2.- / ADP Ribose Transferases; EC 2.4.2.31 / toxA protein, Pseudomonas aeruginosa
  •  go-up   go-down


72. Ueda Y, Yamagishi T, Samata K, Hirayama N, Aozuka Y, Tanaka M, Nakaike S, Saiki I: Antitumor effects of synthetic VEGF-receptor binding antagonist, VGA1155. Anticancer Res; 2005 Nov-Dec;25(6B):3973-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, VEGF and its receptors are considered to be primary targets for antiangiogenic strategy during cancer chemotherapy.
  • VGA1155 suppressed the growth of human lung, breast, colon and epidermoid cancers (LC-6, HT29, MX-1, Col-1 and A431) in the nude mouse xenograft model, and pulmonary metastasis of melanoma in the spontaneous metastasis model.
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Breast Neoplasms / blood supply. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma, Non-Small-Cell Lung / blood supply. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Cell Growth Processes / drug effects. Colonic Neoplasms / blood supply. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Humans. Lung Neoplasms / blood supply. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Melanoma, Experimental / blood supply. Melanoma, Experimental / drug therapy. Melanoma, Experimental / pathology. Mice. Mice, Inbred BALB C. Mice, Nude. Neovascularization, Pathologic / drug therapy. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16309186.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoates; 0 / VGA1155; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


73. Charnley N, Choudhury A, Chesser P, Cooper RA, Sebag-Montefiore D: Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy. Br J Cancer; 2005 Apr 11;92(7):1221-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy.
  • Chemoradiotherapy (CRT) is accepted as the standard initial treatment for squamous cell anal cancer.
  • In all, 16 patients with biopsy-proven squamous cell carcinoma of the anal canal or margin and performance status or co-morbidity precluding the use of full-dose CRT were included in this protocol.
  • Patients received a dose of 30 Gy to the gross tumour volume plus 3 cm margin in all directions.
  • Concurrent chemotherapy comprised 5-fluorouracil 600 mg m(-2) given over 24 h on days 1-4 of radiotherapy.
  • The treatment was well tolerated.
  • All 16 patients completed treatment as planned.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Fluorouracil / therapeutic use. Frail Elderly
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Combined Modality Therapy. Comorbidity. Female. Health Status. Humans. Male. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):65-9 [12118566.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1387-92 [9338461.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):2978-81 [15210736.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] Dis Colon Rectum. 1977 Nov-Dec;20(8):677-8 [923397.001]
  • [Cites] Dis Colon Rectum. 1982 Nov-Dec;25(8):778-82 [7172946.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] Radiother Oncol. 1985 Feb;3(2):145-50 [3920734.001]
  • [Cites] Dis Colon Rectum. 1987 May;30(5):324-33 [3568920.001]
  • [Cites] Dis Colon Rectum. 1987 Jul;30(7):495-502 [3109860.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1115-25 [1938508.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1736-40 [8448738.001]
  • [Cites] Radiology. 1994 May;191(2):569-72 [8153343.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] Br J Cancer. 2003 May 6;88(9):1352-7 [12778060.001]
  • (PMID = 15798772.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2361984
  •  go-up   go-down


74. Kokka F, Vorgias G, Tserkezoglou A, Tsiaousi I, Hadjieleftheriou G, Andriotis M, Akrivos T, Fotiou S, Apostolikas N: Preoperative work-up of early cervical cancer (stages Ib-IIa). Eur J Gynaecol Oncol; 2003;24(2):175-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS: We retrospectively reviewed the medical records of 309 patients with previously untreated early cervical carcinoma who completed pretreatment evaluation at "St. Savas" Cancer Hospital of Athens and "Metaxas" Memorial Hospital of Peireas between January 1986 and September 1, 2000.
  • Histologic type was squamous (267 pts.
  • Patients with early stage cervical carcinoma were treated with Wertheim-Meigs radical hysterectomy and pelvic lymphadenectomy, while those with advanced stage cervical carcinoma were treated with radiotherapy and chemotherapy.
  • CONCLUSION: In our series of patients with early stage cervical carcinoma, imaging and endoscopic tests added limited information over pelvic examination and altered in four cases (1.29%) the choice of the appropriate treatment modality.
  • CT scans proved adequate in this series of patients in the evaluation of the bladder and colon.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Preoperative Care / methods. Urologic Diseases / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Colonoscopy. Cystoscopy. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12701973.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


75. Russo A, Cardile V, Lombardo L, Vanella L, Vanella A, Garbarino JA: Antioxidant activity and antiproliferative action of methanolic extract of Geum quellyon Sweet roots in human tumor cell lines. J Ethnopharmacol; 2005 Sep 14;100(3):323-32
Hazardous Substances Data Bank. HYDROGEN PEROXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antioxidant activity and antiproliferative action of methanolic extract of Geum quellyon Sweet roots in human tumor cell lines.
  • We also examined the anticancer action of this plant on Caco-2 (colon adenocarcinoma cells), DU-145 (androgen-insensitive prostate cancer cells) and KB (oral squamous carcinoma cells) human tumor cell lines.
  • The assays on human tumor cell lines demonstrated that this natural product exhibits a inhibitory effect on all human cancer cells examined, and seem to indicate that necrosis cell death is triggered in KB cells and Caco-2, while apoptotic cell demise appears to be induced in DU-145.
  • [MeSH-minor] Biphenyl Compounds / chemistry. Caco-2 Cells. Cell Line, Tumor. Chelating Agents / chemistry. Chelating Agents / pharmacology. Chile. Comet Assay. DNA, Neoplasm / biosynthesis. DNA, Neoplasm / drug effects. Drug Screening Assays, Antitumor. Enzyme Inhibitors / pharmacology. Free Radical Scavengers / pharmacology. Humans. Hydrazines / chemistry. Hydrogen Peroxide / chemistry. KB Cells. L-Lactate Dehydrogenase / metabolism. Male. Medicine, Traditional. Picrates. Plant Extracts / chemistry. Plant Extracts / pharmacology. Plant Roots / chemistry. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / metabolism. Reactive Oxygen Species / metabolism. Tannins / chemistry. Tannins / isolation & purification. Tannins / pharmacology. Tetrazolium Salts. Thiazoles. Ultraviolet Rays. Xanthine Oxidase / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15941635.001).
  • [ISSN] 0378-8741
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Antioxidants; 0 / Biphenyl Compounds; 0 / Chelating Agents; 0 / DNA, Neoplasm; 0 / Enzyme Inhibitors; 0 / Free Radical Scavengers; 0 / Hydrazines; 0 / Picrates; 0 / Plant Extracts; 0 / Reactive Oxygen Species; 0 / Tannins; 0 / Tetrazolium Salts; 0 / Thiazoles; 1898-66-4 / 2,2-diphenyl-1-picrylhydrazyl; 298-93-1 / thiazolyl blue; BBX060AN9V / Hydrogen Peroxide; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 1.17.3.2 / Xanthine Oxidase
  •  go-up   go-down


76. Peng YF, Gu J: Synchronous colorectal and lung cancer: report of three cases. World J Gastroenterol; 2008 Feb 14;14(6):969-73
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report three cases of patients with tumors located in the rectum, ascending colon, the lower lobe of the left lung, and the upper lobe of the right lung.
  • Pathological examination showed the colorectal cancer was a moderately differentiated adenocarcinoma and the lung cancer was a squamous cell carcinoma.
  • Surgical treatment and postoperative adjuvant chemotherapy for the lung cancer were different from those for colorectal cancer with pulmonary metastasis.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2000 Oct;217(1):257-61 [11012454.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):91-7 [11786770.001]
  • [Cites] Gut. 2002 May;50(5):647-52 [11950810.001]
  • [Cites] Int J Colorectal Dis. 2007 Jun;22(6):699-704 [17109105.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1884-7 [12085180.001]
  • [Cites] Lung Cancer. 2003 Aug;41(2):155-62 [12871778.001]
  • [Cites] Dis Colon Rectum. 1993 May;36(5):425-9 [8482160.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):767-73 [12023581.001]
  • (PMID = 18240362.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2687071
  •  go-up   go-down


77. Lim HJ, Masin D, McIntosh NL, Madden TD, Bally MB: Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J Pharmacol Exp Ther; 2000 Jan;292(1):337-45
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
  • A previous study suggested that drug release is the dominating factor controlling biological activity of liposomal mitoxantrone in tissues where the rate of liposome accumulation is rapid.
  • The studies described here attempted to address the question: under conditions where the rate of liposome accumulation is slow, does drug release or liposome-mediated drug delivery become the dominant factor controlling therapeutic activity?
  • Liposomal mitoxantrone formulations exhibiting different drug-release characteristics were injected i.v. in mice bearing human carcinoma xenografts: A431 human squamous cell carcinoma and LS180 human colon cell carcinoma in SCID/RAG 2 mice.
  • When lipid and drug levels were measured in established (>100-mg) tumors, accumulation was more rapid in the LS180 tumors (C(max) 4 h) than in the A431 tumors (C(max) 48 h).
  • Mean area under the curve values for mitoxantrone measured over a 96-h time course in A431 tumors were 505, 304, and 93 microg. g(-1).
  • Although drug delivery was less after administration of the DMPC/Chol liposomal mitoxantrone compared with the DSPC/Chol formulation, LS180 solid-tumor growth curves showed the treatment with the DMPC/Chol formulation produced greater delays in tumor growth compared with animals treated with the DSPC/Chol formulation.
  • These data emphasize the importance of designing liposomal formulations that release drug after localization within a region of tumor growth.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Cell Division / drug effects. Colonic Neoplasms / drug therapy. Drug Delivery Systems / methods. Liposomes / pharmacokinetics. Mitoxantrone / pharmacokinetics. Mitoxantrone / therapeutic use
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Female. Humans. Mice. Neoplasm Transplantation. Time Factors. Transplantation, Heterologous

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10604968.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Liposomes; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


78. Venkataramani V, Rossner C, Iffland L, Schweyer S, Tamboli IY, Walter J, Wirths O, Bayer TA: Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. J Biol Chem; 2010 Apr 2;285(14):10678-89
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein.
  • The beta-amyloid precursor protein (APP) represents a type I transmembrane glycoprotein that is ubiquitously expressed.
  • Previous studies showed that APP is up-regulated in prostate, colon, pancreatic tumor, and oral squamous cell carcinoma.
  • In this study, we show that APP has an essential role in growth control of pancreatic and colon cancer.
  • Abundant APP staining was found in human pancreatic adenocarcinoma and colon cancer tissue.
  • Interestingly, treating pancreatic and colon cancer cells with valproic acid (VPA, 2-propylpentanoic acid), a known histone deacetylase (HDAC) inhibitor, leads to up-regulation of GRP78, an endoplasmic reticulum chaperone immunoglobulin-binding protein.
  • GRP78 is involved in APP maturation and inhibition of tumor cell growth by down-regulation of APP and secreted soluble APPalpha.
  • VPA did not modify the level of epidermal growth factor receptor, another type I transmembrane protein, and APLP2, a member of the APP family, demonstrating the specificity of the VPA effect on APP.
  • Small interfering RNA-mediated knockdown of APP also resulted in significantly decreased cell growth.
  • Based on these observations, the data suggest that APP down-regulation via HDAC inhibition provides a novel mechanism for pancreatic and colon cancer therapy.
  • [MeSH-major] Amyloid beta-Protein Precursor / metabolism. Anticonvulsants / pharmacology. Cell Proliferation / drug effects. Colonic Neoplasms / prevention & control. Pancreatic Neoplasms / prevention & control. Receptors, Cell Surface / metabolism. Valproic Acid / pharmacology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Psychopharmacol Bull. 2003;37 Suppl 2:5-16 [14624229.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):1079-86 [14871841.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):14456-63 [14732706.001]
  • [Cites] Development. 2004 May;131(9):2173-81 [15073156.001]
  • [Cites] J Biol Chem. 2004 Apr 30;279(18):18851-60 [14985358.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):727-32 [15252842.001]
  • [Cites] Neuropharmacology. 1985 May;24(5):427-35 [3927183.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Oct;85(19):7341-5 [3140239.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(24):9811-5 [2904679.001]
  • [Cites] Cell. 1989 Aug 25;58(4):615-22 [2475254.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):6075-9 [1631093.001]
  • [Cites] FEBS Lett. 1992 Aug 31;309(1):20-4 [1511741.001]
  • [Cites] J Cell Biol. 1993 May;121(4):879-86 [8491779.001]
  • [Cites] Neuroreport. 1993 Jun;4(6):811-4 [8347831.001]
  • [Cites] Nat Genet. 1993 Sep;5(1):95-100 [8220435.001]
  • [Cites] J Biol Chem. 1993 Dec 15;268(35):26571-7 [7504673.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7450-4 [8052602.001]
  • [Cites] J Neurobiol. 1994 May;25(5):585-94 [8071662.001]
  • [Cites] J Neurosci. 1994 Sep;14(9):5461-70 [8083748.001]
  • [Cites] J Biol Chem. 1996 Jan 19;271(3):1613-20 [8576160.001]
  • [Cites] J Biol Chem. 1996 Aug 2;271(31):18295-8 [8756120.001]
  • [Cites] J Biol Chem. 1996 Sep 13;271(37):22908-14 [8798471.001]
  • [Cites] Anticancer Drugs. 1997 Nov;8(10):958-63 [9436639.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1770-5 [9465092.001]
  • [Cites] J Biol Chem. 1998 Mar 13;273(11):6277-84 [9497354.001]
  • [Cites] J Biol Chem. 1998 Oct 2;273(40):25552-5 [9748217.001]
  • [Cites] Prog Neurobiol. 1998 Dec;56(5):541-69 [9775403.001]
  • [Cites] Mech Ageing Dev. 1998 Aug 14;104(2):149-58 [9792193.001]
  • [Cites] Clin Cancer Res. 1995 Jan;1(1):19-31 [9815883.001]
  • [Cites] Anticancer Res. 1998 Sep-Oct;18(5A):3585-9 [9858943.001]
  • [Cites] Mol Pharmacol. 1999 Mar;55(3):521-7 [10051536.001]
  • [Cites] Nat Struct Biol. 1999 Apr;6(4):327-31 [10201399.001]
  • [Cites] Br J Cancer. 2005 Feb 28;92(4):751-9 [15685243.001]
  • [Cites] Med Res Rev. 2005 Jul;25(4):383-97 [15637697.001]
  • [Cites] J Biol Chem. 2005 Jul 29;280(30):28110-7 [15923191.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Jun 2;344(2):525-30 [16630560.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5656-64 [16740703.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7237-44 [16849572.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Nov;319(2):533-42 [16868035.001]
  • [Cites] Cell Biol Int. 2006 Nov;30(11):952-6 [16889988.001]
  • [Cites] Biochem J. 2007 Mar 15;402(3):581-9 [17132139.001]
  • [Cites] Curr Opin Neurol. 2007 Apr;20(2):175-80 [17351488.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2393-400 [17294442.001]
  • [Cites] Cancer Biol Ther. 2007 Feb;6(2):185-91 [17218782.001]
  • [Cites] Brain Res. 2007 Jun 4;1152:209-14 [17428449.001]
  • [Cites] Mol Cell Biol. 2007 Jul;27(13):4784-95 [17470557.001]
  • [Cites] Neurodegener Dis. 2007;4(5):349-65 [17622778.001]
  • [Cites] Bioorg Med Chem Lett. 2007 Aug 15;17(16):4491-4 [17566732.001]
  • [Cites] Cancer Biol Ther. 2007 May;6(5):795-801 [17387270.001]
  • [Cites] Mol Cancer Ther. 2007 Oct;6(10):2626-33 [17913855.001]
  • [Cites] Biochem J. 2008 Jan 15;409(2):581-9 [17868033.001]
  • [Cites] J Neurosci. 2007 Dec 26;27(52):14459-69 [18160654.001]
  • [Cites] Mol Cell Proteomics. 2008 Jan;7(1):15-34 [17934213.001]
  • [Cites] Curr Alzheimer Res. 2008 Apr;5(2):179-86 [18393803.001]
  • [Cites] Cancer Treat Rev. 2008 May;34(3):206-22 [18226465.001]
  • [Cites] J Biol Chem. 2008 Oct 31;283(44):29615-9 [18650430.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):647-55 [18974993.001]
  • [Cites] J Exp Med. 2008 Nov 24;205(12):2781-9 [18955571.001]
  • [Cites] EMBO Rep. 2009 Jan;10(1):94-100 [19057576.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):137-42 [19117996.001]
  • [Cites] Cancer Lett. 2009 May 8;277(1):8-21 [18824292.001]
  • [Cites] J Biol Chem. 2009 May 29;284(22):15016-25 [19336403.001]
  • [Cites] Cancer Lett. 2009 Aug 8;280(2):123-4 [19303208.001]
  • [Cites] Neurology. 2010 Jan 12;74(2):106-12 [20032288.001]
  • [Cites] Mol Cancer Ther. 2009 May;8(5):1086-94 [19417144.001]
  • [Cites] Biochem J. 1999 Dec 1;344 Pt 2:461-7 [10567229.001]
  • [Cites] Mol Psychiatry. 1999 Nov;4(6):524-8 [10578233.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Brain Pathol. 2001 Jan;11(1):1-11 [11145195.001]
  • [Cites] Eur J Cell Biol. 2000 Dec;79(12):905-14 [11152291.001]
  • [Cites] Physiol Rev. 2001 Apr;81(2):741-66 [11274343.001]
  • [Cites] Int J Cancer. 2001 Apr 1;92(1):31-9 [11279603.001]
  • [Cites] J Neurochem. 2001 May;77(4):1077-84 [11359873.001]
  • [Cites] Dev Genes Evol. 2001 Jul;211(7):355-7 [11466532.001]
  • [Cites] J Biol Chem. 2001 Sep 28;276(39):36734-41 [11473107.001]
  • [Cites] EMBO J. 2001 Dec 17;20(24):6969-78 [11742974.001]
  • [Cites] EMBO J. 2002 Jun 3;21(11):2672-81 [12032080.001]
  • [Cites] Curr Med Chem. 2002 Jun;9(11):1107-19 [12052175.001]
  • [Cites] Med Res Rev. 2002 Sep;22(5):492-511 [12210556.001]
  • [Cites] Biochem J. 2003 Mar 15;370(Pt 3):737-49 [12429021.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 17;310(2):529-36 [14521942.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7032-7 [14612490.001]
  • (PMID = 20145244.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APP protein, human; 0 / Amyloid beta-Protein Precursor; 0 / Anticonvulsants; 0 / Histone Deacetylase Inhibitors; 0 / Protease Nexins; 0 / RNA, Small Interfering; 0 / Receptors, Cell Surface; 614OI1Z5WI / Valproic Acid
  • [Other-IDs] NLM/ PMC2856276
  •  go-up   go-down


79. Liang Z, Hu WD, Gu ZD, Xiong HC, Chen KN: [Evaluation of transhiatus esophagectomy for patients with esophageal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Sep;11(5):451-3
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: These 46 patients included 44 esophageal squamous cell carcinomas,1 esophageal adenocarcinoma and 1 esophageal carcinoid.
  • Six patients received preoperative chemotherapy and pathological complete response was seen in 2 cases.
  • Reconstruction with stomach was performed in 42 cases and with colon interposition in 4 cases.All the tumors were resected, and there was no perioperative death.
  • CONCLUSION: Transhiatus esophagectomy is an ideal choice in surgical treatment for patients with esophageal cancer, especially for the ones of aged, poor cardiac or pulmonary function, who can not afford the thoracotomy.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803048.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


80. Goerner M, Seiwert TY, Sudhoff H: Molecular targeted therapies in head and neck cancer--an update of recent developments-. Head Neck Oncol; 2010;2:8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular targeted therapies in head and neck cancer--an update of recent developments-.
  • Targeted therapies have made their way into clinical practice during the past decade.
  • Indeed, in some hematologic malignancies, such as chronic myelogenous leukemia or non-Hodgkin's lymphomas, biologicals and antibodies specifically designed to target tumour-specific proteins have revolutionized treatment standards.
  • In solid tumours, new drugs targeting EGF- or VEGF- receptors are now approved and are entering clinical practise for treatment of colon, lung, kidney and other cancers, either alone or in combination with conventional treatment approaches.
  • Recent data have now shown that molecular targeted therapy might display efficacy in patients with head and neck squamous cell carcinoma (HNSCC) as well.
  • The evaluated biologicals are generally well tolerated from HNSCC patients, who usually have the burden of multiple co-morbidities that interfere with conventional systemic treatment options.
  • Therefore, molecular targeted therapies offer new treatment options even for heavily pretreated and seriously ill patients usually unable to tolerate chemotherapy or radiation therapy.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy. Molecular Targeted Therapy / methods. Receptor, Epidermal Growth Factor / metabolism. Receptors, Vascular Endothelial Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1993 Aug 1;53(15):3579-84 [8339264.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 Sep;17(6):418-24 [16149284.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6924-32 [16203784.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1458-65 [16488554.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2666-72 [16763281.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3766-73 [17704426.001]
  • [Cites] Oral Oncol. 2008 Apr;44(4):361-8 [17689285.001]
  • [Cites] Cancer. 2008 Jun 15;112(12):2710-9 [18481809.001]
  • [Cites] Semin Oncol. 2008 Jun;35(3):274-85 [18544442.001]
  • [Cites] Semin Oncol. 2008 Jun;35(3):286-97 [18544443.001]
  • [Cites] Eur J Cancer. 2008 Sep;44(13):1922-30 [18691881.001]
  • [Cites] Lancet Oncol. 2009 Mar;10(3):247-57 [19201650.001]
  • [Cites] Oncologist. 2009 Mar;14(3):284-90 [19282350.001]
  • [Cites] J Clin Oncol. 2009 Apr 10;27(11):1864-71 [19289630.001]
  • [Cites] Expert Opin Biol Ther. 2009 May;9(5):667-74 [19379120.001]
  • [Cites] Br J Cancer. 2009 May 5;100(9):1379-84 [19401697.001]
  • [Cites] Cancer Biol Ther. 2009 Apr;8(8):696-703 [19276677.001]
  • [Cites] Curr Opin Mol Ther. 2009 Jun;11(3):308-21 [19479664.001]
  • [Cites] Annu Rev Med. 2009;60:207-19 [19630571.001]
  • [Cites] Expert Rev Anticancer Ther. 2009 Oct;9(10):1421-8 [19828002.001]
  • [Cites] Head Neck Oncol. 2009;1:36 [19828033.001]
  • [Cites] Ann Oncol. 2010 Feb;21(2):342-7 [19892746.001]
  • [Cites] Lancet Oncol. 2010 Jan;11(1):21-8 [19897418.001]
  • [Cites] Ann Oncol. 2010 Apr;21(4):864-70 [19850643.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2787-99 [12860957.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6166-73 [15342401.001]
  • [Cites] J Immunol. 2004 Oct 1;173(7):4699-707 [15383606.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1935-40 [10213503.001]
  • (PMID = 20398256.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Other-IDs] NLM/ PMC2868849
  • [General-notes] NLM/ Original DateCompleted: 20100630
  •  go-up   go-down


81. Vogt T, McClelland M, Jung B, Popova S, Bogenrieder T, Becker B, Rumpler G, Landthaler M, Stolz W: Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II. Melanoma Res; 2001 Dec;11(6):587-99
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Basal cell carcinomas (BCCs) and squamous cell carcinomas (SCCs) were also analysed as controls: the BCCs were consistently Cox-II negative (n = 11), whereas the SCCs showed moderate to strong Cox-II expression in 53% (n = 17).
  • Reverse transcription-polymerase chain reaction and Western blotting of MM cell lines and MM tissues confirmed the lack of Cox-II expression in MM.
  • However, in vitro the Cox-inhibiting non-steroidal anti-inflammatory drug (NSAID) sulindac sulphide (SIS) was significantly more effective in inducing apoptosis than sulindac sulphone (SOS), a derivative with a negligible effect on Cox (P < 0.01).
  • The SIS doses needed for the induction of apoptosis were not significantly different in MM cell lines versus a Cox-II-positive colon carcinoma cell line (HT29).
  • We conclude that Cox-II expression is not involved in the progression of MM, and NSAID-induced apoptosis in MM cell lines seems to follow pathways independent of Cox-II.
  • Nevertheless, Cox-II inhibitors are still candidates for therapy, though they act via an unknown mechanism.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Apoptosis / drug effects. Isoenzymes / metabolism. Melanoma / pathology. Prostaglandin-Endoperoxide Synthases / metabolism. Skin Neoplasms / pathology. Sulindac / analogs & derivatives. Sulindac / pharmacology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blotting, Western. Carcinoma, Basal Cell / enzymology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / pathology. Cell Differentiation. Child. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Cyclooxygenase Inhibitors / pharmacology. DNA Primers / chemistry. Disease Progression. Enzyme-Linked Immunosorbent Assay. Humans. Immunoenzyme Techniques. Membrane Proteins. Middle Aged. RNA / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11725205.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / DNA Primers; 0 / Isoenzymes; 0 / Membrane Proteins; 184SNS8VUH / Sulindac; 63231-63-0 / RNA; 6UVA8S2DEY / sulindac sulfide; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; K619IIG2R9 / sulindac sulfone
  •  go-up   go-down


82. Stojkovic R, Karminski-Zamola G, Racane L, Tralic-Kulenovic V, Glavas-Obrovac L, Ivankovic S, Radacic M: Antitumor efficiency of novel fluoro-substituted 6-amino-2-phenylbenzothiazole hydrochloride salts in vitro and in vivo. Methods Find Exp Clin Pharmacol; 2006 Jul-Aug;28(6):347-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A novel series of hydrochloride or dihydrochloride salts of the novel 2-(fluoro-substituted phenyl)-6-aminobenzothiazoles (5-7) have been prepared in multistep synthesis starting from 3- or 4-fluorobenzaldehydes and 2-amino-5-nitrothiophenol and evaluated for their antiproliferative activity against human cervical (HeLa), breast (MCF-7), colon (CaCO-2), and laryngeal (Hep-2) carcinomas and against fibroblast cell lines (WI-38).
  • Also, antitumor activity of these compounds was evaluated in vitro and in vivo against murine melanoma (B16-F10), fibrosarcoma (FsaR), and squamous cell carcinoma (SCCVII).
  • The cytotoxic effect was selective, cell specific, and dose dependent, between 33 microM for MCF-7 and 110 microM for WI-38.
  • All examined benzothiazoles had significant antitumor activity in vivo against melanoma B16-F10, fibrosarcoma, and squamous cell carcinoma.
  • The best therapeutic results were achieved when therapy started 7 days after tumor cell implantation and when benzothiazoles were given repeatedly five times every 2 days, i.e., on day 7, 9, 11, 13, and 15 after transplantation of tumor cells.
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival. DNA, Neoplasm / biosynthesis. Drug Screening Assays, Antitumor. Fibroblasts / drug effects. Fibrosarcoma / drug therapy. Fibrosarcoma / pathology. Humans. Indicators and Reagents. Melanoma, Experimental / drug therapy. Melanoma, Experimental / pathology. Mice. Mice, Inbred C3H. Mice, Inbred C57BL. Neoplasm Proteins / biosynthesis. Neoplasm Transplantation. RNA, Neoplasm / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894403.001).
  • [ISSN] 0379-0355
  • [Journal-full-title] Methods and findings in experimental and clinical pharmacology
  • [ISO-abbreviation] Methods Find Exp Clin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Neoplasm; 0 / Indicators and Reagents; 0 / Neoplasm Proteins; 0 / RNA, Neoplasm; 0 / Thiazoles
  •  go-up   go-down


83. Goldstone SE, Palefsky JM, Winnett MT, Neefe JR: Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis Colon Rectum; 2002 Apr;45(4):502-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Human papillomavirus causes anogenital squamous intraepithelial lesions, warts, and cancer.
  • Treatment of squamous intraepithelial lesions to prevent cancer often requires extensive surgery.
  • Improvement in pathologic diagnosis of patients with persistent high-grade squamous intraepithelial lesions was studied in an open-label trial (HspE7 500 microg monthly x3).
  • The reduction in size in most patients greatly diminished the procedure necessary for complete ablation.
  • This activity crosses multiple human papillomavirus types.
  • [MeSH-major] Anus Diseases / therapy. Anus Neoplasms / therapy. Bacterial Proteins. Carcinoma in Situ / therapy. Carcinoma, Squamous Cell / therapy. Chaperonins / pharmacology. Chaperonins / therapeutic use. Condylomata Acuminata / therapy. Immunotherapy. Oncogene Proteins, Viral / pharmacology. Oncogene Proteins, Viral / therapeutic use. Papillomaviridae / drug effects. Recombinant Fusion Proteins / pharmacology. Recombinant Fusion Proteins / therapeutic use

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - Genital Warts.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12006932.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Chaperonin 60; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / Recombinant Fusion Proteins; 0 / heat-shock protein 65, Mycobacterium; 0 / oncogene protein E7, Human papillomavirus type 16; EC 3.6.1.- / Chaperonins
  •  go-up   go-down


84. Ghouti L, Houvenaeghel G, Moutardier V, Giovannini M, Magnin V, Lelong B, Bardou VJ, Delpero JR: Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer. Dis Colon Rectum; 2005 Jan;48(1):16-22
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer.
  • PURPOSE: Radiotherapy alone or with combined chemotherapy is the first therapeutic option for epidermoid carcinoma of the anal canal.
  • Failure of this conservative treatment may benefit of salvage abdominoperineal resection.
  • METHODS: Medical charts of 36 patients (median age, 57.9 years) who underwent salvage abdominoperineal resection after failure of conservative treatment between 1987 and 2002 were reviewed retrospectively.
  • CONCLUSIONS: Despite high incidence of perineal morbidity, salvage abdominoperineal resection for epidermoid carcinomas of the anal canal has a high long-term survival rate.
  • [MeSH-major] Abdomen / surgery. Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Perineum / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Morbidity. Retrospective Studies. Salvage Therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690652.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Ye F, Xui L, Yi J, Zhang W, Zhang DY: Anticancer activity of Scutellaria baicalensis and its potential mechanism. J Altern Complement Med; 2002 Oct;8(5):567-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Scutellaria baicalensis is a widely used Chinese herbal medicine that historically is used in anti-inflammatory and anticancer therapy.
  • METHODS: Cell lines from the most common human cancers, including squamous cell carcinoma (SCC-25, KB), breast cancer (MCF-7), hepatocellular carcinoma (HepG2), prostate carcinoma (PC-3 and LNCaP), and colon cancer (KM-12 and HCT-15) were tested.
  • Percentage of viable cells after treatment was assessed using a trypan blue dye exclusion assay and the level of PGE(2) production was determined by enzyme immunoassay (EIA).
  • RESULTS: Scutellaria baicalensis demonstrated a strong dose-dependent growth inhibition in all cell lines.
  • Three cell lines (KB, SCC-25, and HepG2) were assessed for the production of PGE(2) and a high level of extracellular (KB and SCC-25) and intracellular PGE(2) (HepG2) was noted.
  • CONCLUSIONS: Scutellaria baicalensis strongly inhibits cell growth in all cancer cell lines tested.
  • However, prostate and breast cancer cells (PC-3, LNCaP, and MCF-7) are slightly more sensitive than other type of cancer cells.
  • It also inhibits PGE(2) production, indicating that suppression of tumor cell growth may be due to its ability to inhibit COX-2 activity.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Dinoprostone / antagonists & inhibitors. Growth Inhibitors / pharmacology. Neoplasms / drug therapy. Phytotherapy / methods. Scutellaria baicalensis
  • [MeSH-minor] Arachidonic Acid / metabolism. Breast Neoplasms / drug therapy. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Squamous Cell / drug therapy. Colonic Neoplasms / drug therapy. Cyclooxygenase 2. Dose-Response Relationship, Drug. Enzyme-Linked Immunosorbent Assay. Female. Humans. In Vitro Techniques. Isoenzymes / metabolism. Liver Neoplasms / drug therapy. Male. Membrane Proteins. Prostaglandin-Endoperoxide Synthases / metabolism. Prostatic Neoplasms / drug therapy. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12470437.001).
  • [ISSN] 1075-5535
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Growth Inhibitors; 0 / Isoenzymes; 0 / Membrane Proteins; 27YG812J1I / Arachidonic Acid; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


86. Marrs J, Zubal BA: Oncology nursing in a new era: optimizing treatment with bevacizumab. Clin J Oncol Nurs; 2009 Oct;13(5):564-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncology nursing in a new era: optimizing treatment with bevacizumab.
  • Overexpression of vascular endothelial growth factor (VEGF) by tumor cells promotes angiogenesis, which correlates with progressive tumor growth and poor outcomes in many types of cancer.
  • Bevacizumab inhibits VEGF to promote regression of tumor vessels by limiting blood supply and tumor growth, enhancing delivery of chemotherapy, and inhibiting formation of new vessels.
  • Combined with chemotherapy, bevacizumab prolongs progression-free and overall survival over chemotherapy alone in patients with metastatic carcinoma of the colon and rectum; unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer (NSCLC); and metastatic HER2-negative breast cancers (mBC).
  • To optimize patient outcomes, nurses should understand bevacizumab's role in cancer therapy, recognize symptoms of toxicity, and manage its side effects.
  • This article describes the rationale for bevacizumab in the treatment of metastatic colorectal cancer, NSCLC, and mBC and discusses patient selection, treatment duration, and side-effect management to support the role of oncology nurses in caring for, educating, and enhancing treatment adherence among patients with cancer receiving bevacizumab.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Oncology Nursing

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19793713.001).
  • [ISSN] 1538-067X
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


87. Nguyen WD, Mitchell KM, Beck DE: Risk factors associated with requiring a stoma for the management of anal cancer. Dis Colon Rectum; 2004 Jun;47(6):843-6
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Combination chemotherapy and radiation therapy has become the standard of care for epidermoid carcinoma of the anus.
  • This treatment modality has allowed for preservation of the anus in most patients, sparing them the morbidity of a stoma.
  • METHODS: Data on all patients with epidermoid carcinoma of the anal canal who were treated with chemoradiation with curative intent at Ochsner Clinic Foundation were entered into a prospective registry.
  • We excluded four patients who were lost to follow-up and one patient who died during chemoradiation therapy.
  • The average radiation dose was 57 +/- 17 Gy.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Colostomy / methods. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / adverse effects. Colectomy. Combined Modality Therapy. Digestive System Diseases / etiology. Digestive System Diseases / surgery. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasm, Residual. Radiotherapy / adverse effects. Risk Factors. Surgical Stomas. Wounds and Injuries / etiology. Wounds and Injuries / surgery

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15054683.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


88. Gevaert O, Daemen A, De Moor B, Libbrecht L: A taxonomy of epithelial human cancer and their metastases. BMC Med Genomics; 2009;2:69
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This technology has the potential to individualize therapy and to discover new drug targets.
  • However, due to technological differences and issues in standardized sample collection no study has evaluated the molecular profile of epithelial human cancer in a large number of samples and tissues.
  • Additionally, it has not yet been extensively investigated whether metastases resemble their tissue of origin or tissue of destination.
  • RESULTS: Large clusters corresponding to breast, gastrointestinal, ovarian and kidney primary tissues emerged from the data.
  • Chromophobe renal cell carcinoma clustered together with follicular differentiated thyroid carcinoma, which supports recent morphological descriptions of thyroid follicular carcinoma-like tumors in the kidney and suggests that they represent a subtype of chromophobe carcinoma.
  • We also found an expression signature identifying primary tumors of squamous cell histology in multiple tissues.
  • In addition, the clustering of colon and breast tumors correlated with clinico-pathological characteristics.
  • Moreover, a signature was developed based on our unsupervised clustering of breast tumors and this was predictive for disease-specific survival in three independent studies.
  • Next, the metastases from ovarian, breast, lung and vulva cluster with their tissue of origin while metastases from colon showed a bimodal distribution.
  • A significant part clusters with tissue of origin while the remaining tumors cluster with the tissue of destination.
  • CONCLUSION: Our molecular taxonomy of epithelial human cancer indicates surprising correlations over tissues.
  • Additionally, we hypothesize that metastases from gastrointestinal origin either remember their tissue of origin or adapt to the tissue of destination.
  • More specifically, colon metastases in the liver show strong evidence for such a bimodal tissue specific profile.
  • [MeSH-minor] Cluster Analysis. Gene Expression Profiling. Genomics. Humans. Internationality. Neoplasms, Unknown Primary / therapy. Oligonucleotide Array Sequence Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2009 Mar;15(3):237-8; author reply 238 [19265816.001]
  • [Cites] Am J Surg Pathol. 2009 Apr;33(4):556-67 [19033864.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2302-10 [19318481.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2009 Jun;21(6):688-92 [19445043.001]
  • [Cites] Mol Syst Biol. 2009;5:273 [19455137.001]
  • [Cites] Nat Rev Cancer. 2009 Jun;9(6):415-28 [19461667.001]
  • [Cites] Am J Pathol. 2009 Jun;174(6):2023-34 [19411448.001]
  • [Cites] Am J Pathol. 2009 Jun;174(6):2035-43 [19411449.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 [11742071.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11890-5 [12185249.001]
  • [Cites] Nat Genet. 2002 Dec;32 Suppl:533-40 [12454650.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):207-14 [12538471.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Nature. 2003 Sep 18;425(6955):307-11 [13679920.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4792-801 [14581350.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):9-16 [14695313.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):453-63 [15087664.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8431-6 [15152076.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9309-14 [15184677.001]
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):497-522 [15369451.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1479-88 [15509519.001]
  • [Cites] Pathol Res Pract. 1983 Mar;176(2-4):284-96 [6856520.001]
  • [Cites] Hepatology. 1996 Mar;23(3):560-70 [8617438.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D562-6 [15608262.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):355-66 [15864277.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Jun;54(3):243-50 [15890271.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4031-40 [15899792.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1503-21 [15931389.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1161-8 [15868237.001]
  • [Cites] Bioinformatics. 2005 Sep 15;21(18):3683-5 [16076888.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13550-5 [16141321.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9155-8 [16230372.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e175 [16284200.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):262-72 [16478745.001]
  • [Cites] Am J Surg Pathol. 2006 Mar;30(3):411-5 [16538064.001]
  • [Cites] Arch Pathol Lab Med. 2006 Apr;130(4):465-73 [16594740.001]
  • [Cites] BMC Genomics. 2006;7:96 [16643655.001]
  • [Cites] J Mol Diagn. 2006 Jul;8(3):320-9 [16825504.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5079-90 [17075127.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10292-301 [17079448.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):529-41 [17157792.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):185-7 [17215538.001]
  • [Cites] Breast J. 2007 Mar-Apr;13(2):172-9 [17319859.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3230-7 [17664471.001]
  • [Cites] Int J Cancer. 2007 Nov 1;121(9):2005-12 [17640062.001]
  • [Cites] BMC Cancer. 2007;7:182 [17894856.001]
  • [Cites] Genome Biol. 2007;8(9):R183 [17784955.001]
  • [Cites] BMC Cancer. 2008;8:88 [18384688.001]
  • [Cites] Nat Med. 2008 May;14(5):518-27 [18438415.001]
  • [Cites] Pathobiology. 2008;75(2):104-11 [18544965.001]
  • [Cites] PLoS Med. 2008 Sep 30;5(9):e184 [18767902.001]
  • [Cites] Breast Cancer Res. 2009;11(1):R7 [19187537.001]
  • [Cites] Breast Cancer Res. 2009;11(2):102 [19344495.001]
  • [Cites] Cancer Biol Ther. 2009 Jun;8(11):1071-9 [19502809.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1231-8 [11583950.001]
  • [Cites] BMC Bioinformatics. 2008;9:271 [18541026.001]
  • [Cites] J Pathol. 2008 Oct;216(2):141-50 [18720457.001]
  • [Cites] Urol Clin North Am. 2008 Nov;35(4):551-61; v [18992609.001]
  • [Cites] Br J Cancer. 2008 Nov 18;99(10):1729-34 [18827815.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):310-8 [19118016.001]
  • [Cites] Semin Oncol. 2009 Feb;36(1):8-37 [19179185.001]
  • [Cites] Semin Oncol. 2009 Feb;36(1):38-43 [19179186.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):790-800 [19228622.001]
  • [Cites] Am J Surg Pathol. 2009 Mar;33(3):393-400 [19047894.001]
  • (PMID = 20017941.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2806369
  •  go-up   go-down


89. Porojnicu AC, Robsahm TE, Dahlback A, Berg JP, Christiani D, Bruland OS, Moan J: Seasonal and geographical variations in lung cancer prognosis in Norway. Does Vitamin D from the sun play a role? Lung Cancer; 2007 Mar;55(3):263-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As judged from the incidence rates of squamous cell carcinoma, the same is true for the average personal UV exposures.
  • We propose, in agreement with earlier findings for prostate-, breast- colon cancer and Hodgkins lymphoma, that a high level of sun-induced 25-hydroxyvitamin D can be a prognostic advantage for certain groups of lung cancer patients, notably for young men.
  • There are two main types of lung cancer: small cell lung cancer for which chemotherapy is the primary treatment and non-small cell lung cancer, which in its early stages is treated primarily with surgery.
  • Gender-related differences have been described in the literature with respect to survival after therapy, male gender being a significant independent negative prognostic factor .
  • In vitro studies, performed with lung cancer cell lines, have shown an inhibitive effect of Vitamin D derivatives on cell-growth and proliferation .
  • Furthermore, animal studies have demonstrated the capability of these compounds to suppress invasion, metastasis and angiogenesis in vivo , suggesting that administration of Vitamin D derivatives may be used as adjuvant therapy for lung cancer.
  • Recently we hypothesised that the seasonal variation of calcidiol might be of prognostic significance for colon-, breast- prostate cancer as well as for Hodgkins lymphoma in Norway.
  • Patients diagnosed during summer and autumn have a better survival after standard treatment than patients diagnosed during the winter season .
  • An American study investigated the effect of season of surgery and recent Vitamin D intake on the survival of non-small cell lung cancer patients.
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / epidemiology. Female. Humans. Male. Middle Aged. Multivariate Analysis. Norway / epidemiology. Prognosis. Proportional Hazards Models. Seafood. Skin Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17207891.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 1406-16-2 / Vitamin D; P6YZ13C99Q / Calcifediol
  •  go-up   go-down


90. Li S, Wang A, Jiang W, Guan Z: Pharmacokinetic characteristics and anticancer effects of 5-fluorouracil loaded nanoparticles. BMC Cancer; 2008;8:103
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: It is expected that prolonged circulation of anticancer drugs will increase their anticancer activity while decreasing their toxic side effects.
  • To study in vivo effects, LoVo cells (human colon cancer cell line) or Tca8113 cells (human oral squamous cell carcinoma cell line) were implanted in BALB/c nude mice that were subsequently treated with 5-FU or 5-FU/PEG-PBLG nanospheres.
  • The drug loading capacity was 27.1% and the drug encapsulation was 61.5%.
  • Compared with a blank control, LoVo cell xenografts and Tca8113 cell xenografts treated with 5-FU or 5-FU/PEG-PBLG nanoparticles grew slower and had prolonged tumor doubling times.
  • 5-Fluorouracil loaded nanoparticles have potential as a novel anticancer drug that may have useful clinical applications.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / pharmacokinetics. Drug Delivery Systems. Fluorouracil / administration & dosage. Fluorouracil / pharmacokinetics. Nanoparticles / therapeutic use
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / ultrastructure. Cell Line, Tumor / drug effects. Colonic Neoplasms / drug therapy. Colonic Neoplasms / ultrastructure. Humans. Mice. Mice, Inbred BALB C. Microscopy, Electron, Scanning. Microscopy, Electron, Transmission. Mouth Neoplasms / drug therapy. Mouth Neoplasms / ultrastructure. Rabbits

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Pharm Sci. 2000 Oct;11 Suppl 2:S81-91 [11033430.001]
  • [Cites] Gan To Kagaku Ryoho. 2000 Jun;27(6):832-45 [10897209.001]
  • [Cites] J Control Release. 2001 May 14;72(1-3):203-15 [11389999.001]
  • [Cites] J Control Release. 2002 May 17;81(1-2):185-99 [11992691.001]
  • [Cites] Int J Pharm. 2003 Sep 16;263(1-2):133-40 [12954188.001]
  • [Cites] Biomaterials. 2003 Dec;24(27):5015-22 [14559015.001]
  • [Cites] Int J Pharm. 2004 Apr 1;273(1-2):29-35 [15010127.001]
  • [Cites] Int J Pharm. 2004 Apr 1;273(1-2):95-107 [15010134.001]
  • [Cites] Yao Xue Xue Bao. 2004 Feb;39(2):149-52 [15127626.001]
  • [Cites] J Drug Target. 2004 Jan;12(1):49-56 [15203911.001]
  • [Cites] Curr Drug Targets. 2004 Jul;5(5):449-55 [15216911.001]
  • [Cites] World J Gastroenterol. 2004 Jul 1;10(13):1989-91 [15222053.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2239-42 [7964937.001]
  • [Cites] Biomaterials. 1995 Nov;16(16):1203-9 [8589188.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):441-51 [8630950.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1450-7 [9552051.001]
  • [Cites] J Control Release. 1998 Jan 23;51(1):1-11 [9685899.001]
  • [Cites] J Control Release. 1998 Feb 12;51(2-3):169-78 [9685914.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):727-31 [9739438.001]
  • [Cites] Pharm Acta Helv. 1999 Feb;73(5):227-36 [10085788.001]
  • [Cites] Int J Pharm. 1999 Apr 20;181(1):107-15 [10370207.001]
  • [Cites] Int J Pharm. 1999 Oct 15;188(1):49-58 [10528082.001]
  • [Cites] Biomacromolecules. 2005 Mar-Apr;6(2):720-5 [15762635.001]
  • [Cites] Int J Pharm. 2005 May 30;296(1-2):151-61 [15885467.001]
  • [Cites] J Control Release. 2005 Jun 2;104(3):477-88 [15911047.001]
  • [Cites] Biomaterials. 2007 Mar;28(9):1730-40 [17182095.001]
  • [Cites] Med Chem. 2007 May;3(3):233-9 [17504194.001]
  • [Cites] Oncol Res. 2007;16(7):313-23 [17518269.001]
  • [Cites] Int J Pharm. 2007 Jun 29;338(1-2):180-90 [17336474.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Jun;7(6):833-7 [17555393.001]
  • [Cites] J Biomed Mater Res A. 2008 Mar 1;84(3):795-804 [17635020.001]
  • [Cites] J Control Release. 2001 Jan 29;70(1-2):63-70 [11166408.001]
  • (PMID = 18412945.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2375900
  •  go-up   go-down


91. Janmaat ML, Giaccone G: The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today (Barc); 2003;39 Suppl C:61-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The epidermal growth factor receptor pathway and its inhibition as anticancer therapy.
  • Epidermal growth factor receptor (EGFR) is commonly overexpressed in a number of epithelial malignancies and is often associated with an aggressive phenotype [e.g., non-small cell lung cancer (NSCLC) and bladder cancer].
  • EGFR is present in over 50% of cases of NSCLC, head and neck squamous cell carcinomas (HNSCC) and colon cancer.
  • Several EGFR-targeting agents have been recently developed (C225, ABX-EGF, E7.6.3, EMD 55900, ICR62, ZD1839, CP358774, PD168393, CGP75166/PKI166, CGP59326A, BIBX1382).
  • In vitro, C225 inhibits EGFR tyrosine kinase activity and proliferation of EGFR-overexpressing squamous cell carcinoma cell lines.
  • This agent, administered intravenously once weekly, is presently in phase III trials in HNSCC and colon cancer.
  • Two large randomized trials have been completed in advanced NSCLC in combination with chemotherapy.
  • Two large randomized phase III studies of ZD1839 have recently been completed and analyzed in which two doses of ZD1839 (250 or 500 mg/day) or placebo were given in combination with two different chemotherapy regimens (carboplatin-paclitaxel or carboplatin-gemcitabine).
  • These studies failed to demonstrate an increase in survival by adding ZD1839 together with chemotherapy in patients with advanced NSCLC.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Neoplasms / drug therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Animals. Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal / therapeutic use. Clinical Trials as Topic. Enzyme Inhibitors / pharmacology. Enzyme Inhibitors / therapeutic use. Humans. Signal Transduction / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14988746.001).
  • [ISSN] 1699-3993
  • [Journal-full-title] Drugs of today (Barcelona, Spain : 1998)
  • [ISO-abbreviation] Drugs Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 128
  •  go-up   go-down


92. Mani S, Vogelzang NJ, Bertucci D, Stadler WM, Schilsky RL, Ratain MJ: Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer; 2001 Sep 15;92(6):1567-76
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Seventy patients with advanced solid malignancies received a total of 220 cycles of combination chemotherapy.
  • Eleven (14.3%) patients received no more than 1 treatment cycle of combination therapy.
  • Three of 30 patients with cytokine refractory renal cell carcinoma (RCC; relative risk [RR] 10 %; 95% confidence interval [CI], 0.82-22%) had a partial response.
  • The remaining 5 responses occurred in 40 patients (RR, 12.5%; 95% CI, 4.2-26.8%): 2 patients with 5-FU refractory colon carcinoma, 1 patient with hepatoma, 1 patient with paclitaxel-cisplatin-resistant ovarian carcinoma, and 1 patient with cisplatin-resistant head and neck squamous cell carcinoma had a partial response.
  • The observed antitumor activity in several solid tumors, especially in renal cell carcinoma, warrants broad Phase II evaluation.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Fluorouracil / administration & dosage. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Anorexia / chemically induced. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / toxicity. Bone Marrow / drug effects. Carcinoma, Renal Cell / drug therapy. Drug Administration Schedule. Fatigue. Female. Humans. Kidney Neoplasms / drug therapy. Male. Middle Aged. Neutropenia / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11745236.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-14599-27
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


93. Sang S, Lambert JD, Tian S, Hong J, Hou Z, Ryu JH, Stark RE, Rosen RT, Huang MT, Yang CS, Ho CT: Enzymatic synthesis of tea theaflavin derivatives and their anti-inflammatory and cytotoxic activities. Bioorg Med Chem; 2004 Jan 15;12(2):459-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Their cytotoxic activities against KYSE 150 and 510 human esophageal squamous cell carcinoma and HT 29 human colon cancer cells were also evaluated.
  • [MeSH-minor] Animals. Arachidonic Acid / metabolism. Biochemistry / methods. Carcinoma, Squamous Cell / drug therapy. Cell Division / drug effects. Cells, Cultured. Colonic Neoplasms / drug therapy. Drug Evaluation, Preclinical / methods. Ear Diseases / chemically induced. Ear Diseases / drug therapy. Edema / chemically induced. Edema / drug therapy. Esophageal Neoplasms / drug therapy. Female. Horseradish Peroxidase / chemistry. Horseradish Peroxidase / metabolism. Humans. Macrophages / drug effects. Macrophages / metabolism. Mice. Mice, Inbred Strains. Structure-Activity Relationship. Tea / chemistry. Tetradecanoylphorbol Acetate / toxicity. Toxicity Tests. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14723964.001).
  • [ISSN] 0968-0896
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA 88961
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Biflavonoids; 0 / Tea; 1IA46M0D13 / theaflavin; 27YG812J1I / Arachidonic Acid; 8R1V1STN48 / Catechin; EC 1.11.1.- / Horseradish Peroxidase; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


94. Koukourakis MI, Giatromanolaki A, Sivridis E, Fezoulidis I: Cancer vascularization: implications in radiotherapy? Int J Radiat Oncol Biol Phys; 2000 Sep 1;48(2):545-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The distribution of the vascular density within tumors was studied in 436 non-small-cell lung carcinomas and 298 breast carcinomas.
  • (1) tumors with low or (2) tumors with high vessel density throughout the tissue section, and (3) tumors with high vessel density in the tumor periphery and low in inner areas.
  • The death rate following surgery showed a direct association with the vascular density in lung, breast, colon, and endometrial cancer.
  • In inoperable gastric cancer patients treated with chemotherapy, and in head and neck cancer patients treated with radical chemoradiotherapy there was a 'U-like' association of the death rate with the vascular density suggesting that very low (poor oxygen and drug availability) and very high (intensified angiogenic pathways) vascularization are both linked to poor outcome.
  • CONCLUSION: The present study stresses the importance of the vascular density as a putative variable that may have affected the results of large clinical trials that investigated the role of anemia, hyperbaric oxygen, hypoxic sensitizers, or even of combined chemoradiotherapy in the outcome of radiation treatment.
  • [MeSH-minor] Adenocarcinoma / blood supply. Adenocarcinoma / radiotherapy. Breast Neoplasms / blood supply. Breast Neoplasms / radiotherapy. Carcinoma, Non-Small-Cell Lung / blood supply. Carcinoma, Non-Small-Cell Lung / radiotherapy. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / radiotherapy. Colonic Neoplasms / blood supply. Colonic Neoplasms / radiotherapy. Endometrial Neoplasms / blood supply. Endometrial Neoplasms / radiotherapy. Female. Humans. Lung Neoplasms / blood supply. Lung Neoplasms / radiotherapy. Microcirculation. Oxygen Consumption. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10974475.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


95. Nishimura M, Daiko H, Yoshida J, Nagai K: Salvage esophagectomy following definitive chemoradiotherapy. Gen Thorac Cardiovasc Surg; 2007 Nov;55(11):461-4; discussion 464-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage esophagectomy following definitive chemoradiotherapy.
  • OBJECTIVES: To evaluate the outcome of salvage surgery following definitive chemoradiotherapy (CRT) for locally advanced esophageal cancer.
  • METHODS: We reviewed patients undergoing salvage esophagectomy from August 2000 through April 2006 at the National Cancer Center Hospital East, following 5-fluorouracil and cisplatinum chemotherapy with concurrent radiotherapy over 50 Gy.
  • RESULTS: Forty-six patients (42 men, all with squamous cell carcinoma) underwent salvage surgery after full-dose concurrent chemoradiotherapy.
  • Salvage surgery consisted of transthoracic esophagectomy, three-field node dissection, and reconstruction with the colon or stomach with vascular restoration.
  • Operation time ranged from 257 to 602 min.
  • The median survival time from salvage surgery was 12 months and that from CRT was 22 months.
  • [MeSH-major] Esophageal Neoplasms / surgery. Esophagectomy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 1997 Nov;114(5):811-5; discussion 816 [9375611.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Oct;126(4):1168-73 [14566264.001]
  • [Cites] Ann Thorac Surg. 2003 Feb;75(2):337-41 [12607635.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Aug;124(2):270-7 [12167786.001]
  • [Cites] JAMA. 1999 May 5;281(17):1623-7 [10235156.001]
  • [Cites] N Engl J Med. 1992 Jun 11;326(24):1593-8 [1584260.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Jan;123(1):175-83 [11782772.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):425-33 [12957254.001]
  • (PMID = 18049854.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


96. Saba NF, Khuri FR, Shin DM: Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. Oncology (Williston Park); 2006 Feb;20(2):153-61; discussion 162, 166, 169 passim
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The epidermal growth factor receptor (EGFR) promotes the growth of different cell types and has been implicated in tumorigenesis.
  • The EGFR comprises a family of four structurally similar tyrosine kinases with a complex link to downstream signaling molecules that ultimately regulate key cell processes.
  • Anti-EGFR agents have been developed as promising therapeutic anticancer targets, and some have been recently approved for the treatment of non-small-cell lung cancer and colon cancer.
  • The two anti-EGFR therapies with the greatest clinical application are monoclonal antibodies that block the binding of ligands to EGFR and small-molecule tyrosine kinase inhibitors that inhibit the binding of adenosine triphosphate to the internal tyrosine kinase receptor of EGFR.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Head and Neck Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Receptor, Epidermal Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Humanized. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cetuximab. Clinical Trials as Topic / methods. Combined Modality Therapy / methods. Erlotinib Hydrochloride. Female. Humans. Male. Mice. Protein Kinase Inhibitors / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Quinazolines / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16562649.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab; S65743JHBS / gefitinib
  • [Number-of-references] 91
  •  go-up   go-down


97. Cao S, Durrani FA, Rustum YM: Synergistic antitumor activity of capecitabine in combination with irinotecan. Clin Colorectal Cancer; 2005 Jan;4(5):336-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 5-Fluorouracil (5-FU) and capecitabine alone and in combination with irinotecan/oxaliplatin are clinically active in the treatment of colorectal and other solid tumors.
  • Studies of the antitumor activity and toxicity of capecitabine or irinotecan alone and in combination with each other, were compared with 5-FU and raltitrexed in human tumor xenografts of colorectal and squamous cell carcinoma of the head and neck using clinically relevant schedules.
  • Antitumor activity and toxicity were evaluated in nude mice bearing human colon carcinomas of HCT-8 and HT-29 and in head and neck squamous cell carcinomas of A253 and FaDu xenografts using the maximum tolerable dose of single-agent capecitabine, 5-FU, or raltitrexed, or each of the drugs in combination with irinotecan.
  • ]), with each drug alone or in combination, and (2) capecitabine orally 5 days a week for 3 weeks and irinotecan 50 mg/kg (I.V. injection) once a week for 3 weeks, with each drug alone or in combination.
  • For comparative purposes, the antitumor activity of single-agent capecitabine, 5-FU, or raltitrexed, or each drug in combination with irinotecan was carried out at its maximum tolerated dose (MTD) using a 3-week schedule.
  • The combination of irinotecan/capecitabine was much more active than either drug alone against all 4 tumor models.
  • The potential impact of the preclinical results on clinical practice for the use of these drugs in combination needs clinical validation.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Camptothecin / analogs & derivatives. Camptothecin / pharmacology. Colonic Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Deoxycytidine / pharmacology
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Capecitabine. Cell Line, Tumor. Dose-Response Relationship, Drug. Drug Synergism. Female. Fluorouracil / pharmacology. Maximum Tolerated Dose. Mice. Mice, Nude. Neoplasm Transplantation. Quinazolines / pharmacology. Thiophenes / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Colorectal Cancer. 2005 Jan;4(5):344 [15663839.001]
  • (PMID = 15663838.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 0 / Thiophenes; 0H43101T0J / irinotecan; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; FCB9EGG971 / raltitrexed; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


98. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res; 2004 Sep-Oct;24(5A):2783-840
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies.
  • Besides cardioprotective effects, resveratrol exhibits anticancer properties, as suggested by its ability to suppress proliferation of a wide variety of tumor cells, including lymphoid and myeloid cancers; multiple myeloma; cancers of the breast, prostate, stomach, colon, pancreas, and thyroid; melanoma; head and neck squamous cell carcinoma; ovarian carcinoma; and cervical carcinoma.
  • The growth-inhibitory effects of resveratrol are mediated through cell-cycle arrest; upregulation of p21Cip1/WAF1, p53 and Bax; down-regulation of survivin, cyclin D1, cyclin E, Bcl-2, Bcl-xL and clAPs; and activation of caspases.
  • Besides chemopreventive effects, resveratrol appears to exhibit therapeutic effects against cancer.
  • Currently, structural analogues of resveratrol with improved bioavailability are being pursued as potential therapeutic agents for cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Neoplasms / drug therapy. Neoplasms / prevention & control. Stilbenes / therapeutic use


99. Sermier A, Gervaz P, Egger JF, Dao M, Allal AS, Bonet M, Morel P: Lymph node retrieval in abdominoperineal surgical specimen is radiation time-dependent. World J Surg Oncol; 2006;4:29
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymph node retrieval in abdominoperineal surgical specimen is radiation time-dependent.
  • BACKGROUND: A low yield of lymph nodes (LN) in abdominoperineal resection (APR) specimen has been associated with preoperative radiation therapy (XRT) in population-based studies, which may preclude adequate staging of anorectal carcinomas.
  • 2) Dose of pelvic irradiation; and 3) Time interval between the end of XRT and surgery.
  • There were 12 patients operated for squamous cell carcinoma of the anal canal (SCCA) and 90 for rectal cancer.
  • Finally, there was an inverse correlation between the yield of LN and the time elapsed between XRT and surgery (linear regression coefficient r = -0.32, p = 0.03).
  • 1) radiation therapy affects the yield of LN retrieval in APR specimen;.
  • 2) this impact is time-dependent.
  • These findings have important implications with regard to anatomic-pathological staging of anal and rectal cancers and subsequent decision-making regarding adjuvant chemotherapy.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]
  • [Cites] Dis Colon Rectum. 1999 Jun;42(6):770-5 [10378601.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2329-35 [9191520.001]
  • [Cites] Cancer Invest. 1996;14(1):1-5 [8597886.001]
  • [Cites] Front Radiat Ther Oncol. 1994;28:37-45 [7982602.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1371-7 [15817339.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1129-35 [15752893.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):665-77 [15708244.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):219-25 [15687365.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):426-31 [15667963.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(2):272-9 [15661553.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1767-72 [15622567.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1408-9 [15467022.001]
  • [Cites] Colorectal Dis. 2004 Sep;6(5):356-61 [15335370.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):1065-71 [15329917.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):279-86 [14991488.001]
  • [Cites] Ann Surg Oncol. 2004 Feb;11(2):187-91 [14761922.001]
  • [Cites] Ann Surg Oncol. 2003 Oct;10(8):903-9 [14527909.001]
  • [Cites] Swiss Med Wkly. 2003 Jun 28;133(25-26):353-9 [12947531.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):668-72 [12586804.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):7-13 [11961595.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):452 [11466702.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):666-72 [9708929.001]
  • (PMID = 16749931.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1524768
  •  go-up   go-down


100. Nagpal S, Na S, Rathnachalam R: Noncalcemic actions of vitamin D receptor ligands. Endocr Rev; 2005 Aug;26(5):662-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Physiological and pharmacological actions of 1,25-(OH)(2)D(3) in various systems, along with the detection of VDR in target cells, have indicated potential therapeutic applications of VDR ligands in inflammation (rheumatoid arthritis, psoriatic arthritis), dermatological indications (psoriasis, actinic keratosis, seborrheic dermatitis, photoaging), osteoporosis (postmenopausal and steroid-induced osteoporosis), cancers (prostate, colon, breast, myelodysplasia, leukemia, head and neck squamous cell carcinoma, and basal cell carcinoma), secondary hyperparathyroidism, and autoimmune diseases (systemic lupus erythematosus, type I diabetes, multiple sclerosis, and organ transplantation).
  • As a result, VDR ligands have been developed for the treatment of psoriasis, osteoporosis, and secondary hyperparathyroidism.
  • Furthermore, encouraging results have been obtained with VDR ligands in clinical trials of prostate cancer and hepatocellular carcinoma.
  • [MeSH-minor] Animals. Autoimmune Diseases / drug therapy. Autoimmune Diseases / metabolism. Humans. Ligands. Mice. Models, Molecular. Neoplasms / drug therapy. Neoplasms / metabolism. Osteoporosis / drug therapy. Osteoporosis / metabolism. Psoriasis / drug therapy. Psoriasis / metabolism

  • MedlinePlus Health Information. consumer health - Vitamin D.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15798098.001).
  • [ISSN] 0163-769X
  • [Journal-full-title] Endocrine reviews
  • [ISO-abbreviation] Endocr. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ligands; 0 / Receptors, Calcitriol; 1406-16-2 / Vitamin D
  • [Number-of-references] 284
  •  go-up   go-down






Advertisement